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ABSTRACT 
Purpose of the study - Identify predictors of mortality and develop a related care plan 
for patients who are on antiretroviral therapy (ART) in Gondar, Ethiopia.  
 
Design - A quantitative, retrospective cohort study was conducted analysing medical 
records of HIV patients who presented to Gondar University Hospital (GUH), Gondar, 
and started ART between 1 January 2007 and 30 June 2010.  
 
Results - In defining the predictors of mortality, the findings in bivariate analysis re-
vealed: female sex, CD4 cell count ≤ 50/µl, CD4 cell count 51-199/µl, a haemoglobin 
concentration ≤8g/dl, a history of oral candidiasis, tuberculosis and Cryptococcus men-
ingitis were all statistically significant. A female sex, CD4 cell count ≤ 50/µl and CD4 cell 
count 51-199/µl maintain their significance level in the multivariate analysis.  
 
Conclusions - The study therefore recommends that clinicians and case managers be 
vigilant of these predictors of mortality while managing HIV patients who are on ART. 
 
Key Concepts- ART, AIDS, HIV, predictors of mortality 
v 
 
 
 
TABLE OF CONTENTS 
 
LIST OF FIGURES .......................................................................................................... x 
LIST OF TABLES ........................................................................................................... xi 
LIST OF ABBREVIATIONS ........................................................................................... xii 
LIST OF ANNEXURES ..................................................................................................xiii 
CHAPTER 1 ORIENTATION TO THE STUDY ............................................................... 1 
1.1 INTRODUCTION ....................................................................................................... 1 
1.2 BACKGROUND OF THE PROBLEM ........................................................................ 2 
1.2.1 Statement of the research problem ..................................................................... 3 
1.3 AIM OF THE STUDY ................................................................................................. 3 
1.3.1 Research purpose ............................................................................................... 3 
1.3.2 Research objectives ............................................................................................ 3 
1.4 SIGNIFICANCE OF THE STUDY .............................................................................. 4 
1.5 DEFINITIONS OF KEY CONCEPTS ......................................................................... 4 
1.6 RESEARCH DESIGN ................................................................................................ 5 
1.6.1 Quantitative ......................................................................................................... 5 
1.6.2 Analytical ............................................................................................................. 5 
1.6.3 Retrospective cohort ........................................................................................... 5 
1.7 RESEARCH METHODS ............................................................................................ 6 
1.7.1 Patients’ records and sample .............................................................................. 6 
1.7.1.1 Study groups ................................................................................................. 6 
1.7.1.2 Sampling method .......................................................................................... 6 
1.7.1.3 Criteria for eligibility / exclusion ..................................................................... 7 
1.7.2 Data collection ..................................................................................................... 8 
1.7.3 Data analysis ....................................................................................................... 8 
1.8 DESIGN VALIDITIES AND RELIABILITIES .............................................................. 8 
1.8.1 Validity ................................................................................................................. 8 
vi 
 
 
1.8.2 Reliability ............................................................................................................. 9 
1.9 ETHICAL CONSIDERATIONS .................................................................................. 9 
1.10 CONCLUSIONS ...................................................................................................... 9 
CHAPTER 2 LITERATURE REVIEW............................................................................ 10 
2.1 INTRODUCTION ..................................................................................................... 10 
2.2 PURPOSE OF THE LITERATURE REVIEW ........................................................... 10 
2.3 OVERVIEW OF HIV ................................................................................................ 10 
2.3.1 Global HIV burden ............................................................................................. 11 
2.3.2 HIV burden in Sub-Saharan Africa .................................................................... 11 
2.3.3 HIV burden in Ethiopia....................................................................................... 12 
2.4 ANTI RETROVIRAL TREATMENT .......................................................................... 12 
2.4.1 Millennium Development Goals ......................................................................... 13 
2.4.2 Progress made in Ethiopia ................................................................................ 14 
2.5 DEATH IN PEOPLE LIVING WITH HIV ................................................................... 15 
2.5.1 Death while on Pre ART .................................................................................... 15 
2.5.2 Death while on ART .......................................................................................... 16 
2.6 ADHERENCE TO ANTIRETROVIRAL TREATMENT ............................................. 17 
2.6.1 Reasons for non-adherence .............................................................................. 18 
2.6.1.1 Difficulties related to social factors and life styles ....................................... 18 
2.6.1.2 Difficulties related to negative beliefs about the use of ART ....................... 18 
2.6.1.3 Difficulties directly related to the use of medication..................................... 19 
2.6.2 Barriers for optimal ART-adherence .................................................................. 19 
2.6.3 Virologic Failure ................................................................................................. 19 
2.7 IMMUNO RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) .................... 20 
2.8 PREDICTORS OF HIV/AIDS ASSOCIATED MORTALITIES .................................. 21 
2.8.1 Poor resource settings....................................................................................... 21 
2.8.2 Malnutrition ........................................................................................................ 22 
2.8.3 Opportunistic infections ..................................................................................... 22 
vii 
 
 
2.9 COMMON LIFE-THREATENING OPPORTUNISTIC INFECTIONS........................ 22 
2.9.1 Pulmonary Tuberculosis .................................................................................... 23 
2.9.2 Toxoplasmosis .................................................................................................. 24 
2.9.3 Pneumocystis Jirovecii Pneumonia ................................................................... 24 
2.9.4 Cryptococcus Meningitis.................................................................................... 24 
2.10 SUMMARY ............................................................................................................ 25 
CHAPTER 3 RESEARCH DESIGN AND METHOD ..................................................... 26 
3.1 INTRODUCTION ..................................................................................................... 26 
3.2 RESEARCH DESIGN .............................................................................................. 26 
3.2.1 Quantitative study .............................................................................................. 26 
3.2.2 Analytical study ................................................................................................. 27 
3.2.3 Cohort study ...................................................................................................... 27 
3.2.3.1 Prospective cohort study ............................................................................. 27 
3.2.3.2 Retrospective cohort study .......................................................................... 28 
3.2.3.3 Strength of a cohort study ........................................................................... 28 
3.2.3.4 Limitations of a cohort study........................................................................ 28 
3.3 RESEARCH METHOD ............................................................................................ 29 
3.3.1 Study population ................................................................................................ 29 
3.3.2 Screening tool ................................................................................................... 29 
3.3.3 Sampling ........................................................................................................... 30 
3.3.4 Sampling error ................................................................................................... 31 
3.3.5 Research assistant ............................................................................................ 32 
3.3.6 Data collection approach and method ............................................................... 32 
3.3.7 Data collection instrument ................................................................................. 32 
3.3.8 Data analysis ..................................................................................................... 33 
3.4 RELIABILITY AND VALIDITY .................................................................................. 34 
3.4.1 Reliability ........................................................................................................... 34 
3.4.2 Validity ............................................................................................................... 34 
viii 
 
 
3.5 ETHICAL CONSIDERATION ................................................................................... 35 
3.6 CONCLUSION ......................................................................................................... 36 
CHAPTER 4 ANALYSIS, PRESENTATION AND DESCRIPTION OF 
THE RESEARCH FINDING ........................................................................................... 37 
4.1 INTRODUCTION ..................................................................................................... 37 
4.2 DATA MANAGEMENT AND ANALYSIS ................................................................. 37 
4.3 RESEARCH RESULTS ........................................................................................... 37 
4.3.1 Sample characteristics (N=1000) ...................................................................... 37 
4.3.1.1 Sex .............................................................................................................. 38 
4.3.1.2 Age .............................................................................................................. 39 
4.3.1.3 Status of the patient .................................................................................... 41 
4.3.2 Follow-up history ............................................................................................... 41 
4.3.2.1 CD4 count ................................................................................................... 42 
4.3.2.2 Haemoglobin count ..................................................................................... 45 
4.3.2.3 History of Oral Candidiasis .......................................................................... 47 
4.3.2.4 History of Tuberculosis ................................................................................ 49 
4.3.2.5 History of Cryptococcus Meningitis ............................................................. 51 
4.4 OVERVIEW OF THE RESEARCH FINDING ........................................................... 53 
4.5 CONCLUSION ......................................................................................................... 54 
CHAPTER 5 CONCLUSIONS AND RECOMMENDATIONS  ....................................... 55 
5.1 INTRODUCTION ..................................................................................................... 55 
5.2 RESEARCH DESIGN AND METHOD ..................................................................... 55 
5.3 SUMMARY AND INTERPRETATION OF THE RESEARCH FINDINGS ................. 56 
5.3.1 Demographic information .................................................................................. 56 
5.3.2 Follow-up history ............................................................................................... 56 
5.4 CONCLUSIONS OF THE STUDY ........................................................................... 57 
5.5 RECOMMENDATIONS ........................................................................................... 59 
5.6 CONTRIBUTIONS OF THE STUDY ........................................................................ 60 
ix 
 
 
5.7 LIMITATIONS OF THE STUDY ............................................................................... 60 
5.8 CONCLUDING REMARKS ...................................................................................... 61 
REFERENCES .............................................................................................................. 62 
ANNEXURES ................................................................................................................ 70 
 
 
 
x 
 
 
LIST OF FIGURES 
 
Figure 4.1: Sex distribution in the dead and alive HIV patients; GUH ART clinic patients 
chart review ...................................................................................................... 39 
 
Figure 4.2: Age distribution in the dead and alive HIV patients; GUH ART clinic patients 
chart review ...................................................................................................... 41 
 
Figure 4.3: CD4 group distribution in the dead and alive HIV patients; GUH ART clinic 
patients chart review .......................................................................................... 44 
 
Figure 4.4: Haemoglobin group distribution in the dead and alive HIV patients; GUH 
ART clinic patients chart review ....................................................................... 47 
 
Figure 4.5: History of Oral Candidiasis distribution in the dead and alive HIV patients; 
GUH ART clinic patients chart review .............................................................. 49 
 
Figure 4.6: History of Tuberculosis distribution in the dead and alive HIV patients; GUH 
ART clinic patients chart review ......................................................................... 51 
 
Figure 4.7: History of Cryptococcus Meningitis distribution in the dead and alive HIV 
patients; GUH ART clinic patients chart review ................................................. 53 
 
 
 
 
 
 
 
xi 
 
 
LIST OF TABLES 
Table 2.1: Adherence to ARV drugs  
 
Table 2.2: Correlation between adherence and virologic response to ART  
 
 
Table 4.1: Sex distribution in the chart review of HIV patients who were on ART 
follow-up at GUH from 1January 2007 – 30 June 2010 
 
Table 4.2: Age group distributions from the chart review of HIV patients who 
were on ART follow-up from 1 January 2007 - 30 June 2010 at GUH. 
 
Table 4.3: CD4 groups distribution from the chart review of HIV patients who 
were on ART follow-up from 1 January 2007 to 30 June 2010 at GUH. 
 
Table 4.4: Bivariate analysis of CD4 count and Bio-status of the patients 
 
 
Table 4.5: Haemoglobin count groups distribution from the chart review of HIV 
patients who were on ART follow-up from 1 January 2007 to 30 June 
2010 at GUH. 
 
Table 4.6: Bivariate analysis of Haemoglobin count and Bio-status of the patients 
 
Table 4.7: The distribution of Oral Candidiasis in the reviewed HIV patients’ 
charts who had ART follow-up at GUH from 1 January 2007 - 30 June 
2010 at GUH. 
 
Table 4.1: Bivariate analysis of History of Oral Candidiasis and Bio-status of the 
patients 
 
Table 4.9: The distribution of Tuberculosis in the reviewed HIV patients’ charts 
who had ART follow-up at GUH from 1 January 2007 - 30 June 2010 at 
GUH. 
 
 
Table 4.10: Bivariate analysis of History of TB and Bio-status of the patients 
 
Table 4.11: The distribution of Cryptococcus Meningitis in the reviewed HIV pa-
tients’ charts who had ART follow-up at GUH from 1 January 2007 - 30 
June 2010 at GUH. 
 
Table 4.2: Bivariate analysis of History of Cryptococcus Meningitis and Bio-
status of the patients 
 
Table 5.1: Care plan for PLWHIV who are on ART and has mortality predictor 
indicators 
xii 
 
 
 
LIST OF ABBREVIATIONS 
 
ACM:   Adherence Case Manager 
AIDS:   Acquired Immunodeficiency Virus 
ARC:   AIDS Resource Centre 
ART:   Anti Retroviral Therapy 
ARV:   Anti Retroviral 
CDC:   Centre for Disease Control and prevention 
ECA:   Economic Commission for Africa 
GUH:   Gondar University Hospital 
HAART:  Highly Active Antiretroviral Treatment 
HAPCO:  HIV/AIDS Prevention and Control Office 
HIV:   Human Immunodeficiency Virus 
I-TECH:  International Training and Education Centre for Health 
LTFU:  Lost To Follow-UP 
MDG:   Millennium Development Goal 
MOH:   Ministry of Health 
NGO:   Non Governmental Organization 
OI:   Opportunistic Infection 
PCP:   Pneumocystis Jirovecii Pneumonia 
PEPFAR:  Presidential Emergency Plan For AIDS Relief 
PLWHIV:  People Living with HIV 
PMTCT:  Prevention of Mother-to-Child-Transmission 
SNNPR:  Southern Nation and Nationality People Region 
SPSS:  Statistical Package for Social Science 
TB:   Tuberculosis 
TI:   Transferred In 
TO:   Transferred Out 
UN:   United Nations 
UNAIDS:  United Nations Programme on HIV/AIDS 
UNISA:  University of South Africa 
WHO:  World Health Organization 
 
xiii 
 
 
 
 
LIST OF ANNEXURES 
 
Annexure A: Time frame 
 
Annexure B: Budget 
 
Annexure C: Data collection instrument 
 
Annexure D: Federal Ministry of Health, Ethiopia HIV care/ART 
follow-up form 
 
Annexure E: Letter asking for permission to conduct the re-
search at GUH                                                                                                
 
Annexure F: Approval from Gondar University Hospital 
 
Annexure G: Ethical clearance from UNISA 
 
Annexure H: Ethical clearance from Gondar University 
 
 
 
 
 
1 
 
 
CHAPTER 1 
ORIENTATION TO THE STUDY 
 
1.1 INTRODUCTION 
 
According to the World Health Organization (WHO), there are 33.4 million people living 
with Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome 
(HIV/AIDS) worldwide (WHO 2010c). In Sub Saharan Africa, where HIV/AIDS is a lead-
ing cause of morbidity and mortality, there resides 22 million people  living with Human 
Immunodeficiency Virus (PLWHIV), making 67% of the global total. According to Ethio-
pian calibrated single point estimate sentinel surveillance 2007, the prevalence of adult 
infection was 2.4 (urban 7.7%, rural 0.9%), adult HIV incidence was 0.29% (urban 
2.04%, rural 0.2%) with a total HIV positive population of 1,216,908 (urban 760,475, ru-
ral 456,432) (Ethiopia AIDS resource centre 2010b). 
 
To curtain such a huge health problem, the Ethiopian government in collaboration with 
Presidential Emergency Plan For AIDS Relief (PEPFAR) has engaged in tackling the 
HIV / AIDS epidemic using divers interventions; the major action being availing free ac-
cess to drugs for Antiretroviral therapy (ART) and Opportunistic Infections (OI). This ac-
tion was launched in January 2005 (Ethiopia AIDS resource centre 2010a). With this 
major action in place it has been possible to significantly decrease HIV associated mor-
talities on a large scale. Compared to the pre ART era where AIDS related mortality was 
very high in Ethiopia, 134,450 (Federal Ministry of Health 2006), free and easy access 
to ART and OI treatment has been showing an improvement in the general morbidity 
and mortality of PLWHIV. The current 2010 Ethiopian national data showed that AIDS 
related death has declined to 28,073 (Ethiopia AIDS resource centre 2010b). 
 
According to the Ethiopian administrative  structure, the country is organized in two fed-
eral cities (Addis Ababa, Dire Dawa) and nine regional states (Harari, Amhara, Tigray, 
Gambella, Afar, Benishangule Gumuz, Oromia, Southern Nations and Nationalities 
People Region (SNNPR), Somali) (WHO 2010b; Federal Ministry of Health 2006). 
These regions have their own different geographical topography, language, culture and 
socioeconomic strata. Moreover, different disease entities have different epidemiologi-
cal distributions. By the same token, HIV / AIDS show a typical distribution pattern 
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among the regions. Amhara, Oromia, Addis Ababa and SNNPR accounted for 86.6% of 
all PLWHIV and 88.2% of AIDS deaths that occurred in Ethiopia in 2005; the regions 
large population size and high HIV prevalence played the major role (WHO 2010b; Fed-
eral Ministry of Health 2006). 
 
1.2 BACKGROUND OF THE PROBLEM 
 
Amhara national regional state, with the population size of 17.2 million which is pre-
dominantly 87.3% of rural residence, is located in the mid-northern part of Ethiopia. 
There are 17 government hospitals (including one university hospital: Gondar University 
Hospital (GUH)), 199 health centres, 2621 health posts, two regional public health re-
search laboratories, and 765 private health facilities (Amhara National Regional State 
Health Bureau 2009).  
 
GUH is a tertiary referral teaching hospital with 350 beds giving service to more than 5 
million people living in the vicinity areas. The hospital started to provide HIV/AIDS re-
lated services in 2003 with limited scope for shortage of trained man power and fee 
based Antiretroviral (ARV) drugs. In March 2005, the hospital scaled up its HIV/AIDS 
related care with the introduction of free ART service. Currently, the hospital is fully 
staffed with highly trained HIV/AIDS health care providers and is greatly supported by a 
PEPFAR funded international Non Governmental Organization (NGO), International 
Training and Education Centre for Health (I-TECH), in the area of capacity building with 
technical and financial support. According to GUH June 2010 hospital HIV/AIDS report, 
there has been a total of 8377 patients enrolled to the HIV care program, out of which 
5566 patients started ART. Around 858 patients have been transferred out (TO) to other 
ART centres and 397 patients were transferred in (TI) to the hospital. In the same re-
port, there are a cumulative 855 patients who were dropped out and 152 lost from fol-
low-up patients making the overall active patients on ART to 3370 (Gondar University 
Hospital 2010).  
 
The researcher was working in the capacity of physician mentor in one of the major in-
ternational NGOs. This NGO gives technical and capacity building support for hospitals 
in Amhara region in the area of HIV/AIDS. This was a great privilege and a great oppor-
tunity to further look in-depth at the challenges of the hospital’s ART clinic. From all the 
hospitals under I-TECH’s scope of work, GUH has one of the most crowded and over-
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loaded ART clinics. In this clinic, there is a huge mortality report in PLWHIV who were 
on ART service. Therefore the source of the research problem arises from the clinical 
experience. 
 
1.2.1 Statement of the research problem 
 
Although increased access to ART is likely to reduce mortality, under the prevailing 
conditions, the cumulative deaths in the hospital are 732 making AIDS deaths among 
PLWHIV who have been on HIV/AIDS care 14.3% according to the June 2010 GUH 
monthly report (GUH 2010). The predictors of mortality in accordance to clinical and 
laboratory findings in adult PLWHIV who are currently on ART are not well studied and 
understood in Ethiopia at large and GUH in particular. 
 
1.3 AIM OF THE STUDY 
 
The aim of the study is to describe predictors of mortality among PLWHIV at GUH ART 
clinic. 
 
1.3.1 Research purpose 
 
The purpose of this study is to develop a simple medical care plan to assist clinicians 
and adherence case managers prioritise defined predictors of mortality among HIV posi-
tive patients on ART at GUH ART clinic, Gondar, Ethiopia  
 
1.3.2 Research objectives 
 
The following objectives guided this study: 
 
 To determine the predictors of mortality among PLWHIV who were on follow-up 
at GUH ART clinic by analysing their records.  
 To develop a care plan for PLWHIV based on the mortality predictors at GUH 
ART clinic. 
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1.4 SIGNIFICANCE OF THE STUDY 
 
This study will benefit PLWHIV, currently on ART care, an intensified review of docu-
ments will probably detect clinical or laboratory disorders which were overlooked in the 
previous times. 
 
Adherence Case Managers (ACMs) will also be assisted in the development of care 
plan, which can further extend to secure funds from local and international NGOs work-
ing with GUH to strengthen patient support programs by presenting evidence based 
problems. 
 
1.5 DEFINITIONS OF KEY CONCEPTS 
 
These concepts are regularly referred to in this study: 
 
Active patients on ART: Attended the last scheduled visit at the ART clinic at Gondar 
University Hospital (GUH protocol). 
 
Adherence Case Managers: Lay health workers who are trained to give adherence       
counselling support for PLWHIV (GUH protocol). 
 
Adherence: Extent to which patients take medications as prescribed by their health 
care provider (Osterberg and Blaschke 2005).  
 
Mortality: Death from all causes which happened at any time after the patient started    
ART; deaths registered from hospital records or reported through out-reach 
workers (GUH protocol). 
 
Predictors of mortality: Clinical or laboratory values which help to forecast death before 
happening for PLWHIV who are on ART.  
 
Weight loss: A decrease in body weight resulting from involuntary (illness) circum-
stances. (Med term 2010) 
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1.6 RESEARCH DESIGN 
 
The research design in this study was quantitative, analytical, retrospective cohort study 
(chapter three discusses in detail).   
 
1.6.1 Quantitative 
 
Quantitative studies require the researcher to measure variables, express associations 
and relationships among variables using statistics; may also be used to examine and 
determine causality (Burns and Groove 2005:747). 
 
Stommel and Wills (2004:442) describes a quantitative research as a method that en-
ables one to measure and describe phenomena’s in standardized numerical scales 
which are analyzed statistically. This research will analyse patients’ clinical and labora-
tory chart/records with the mortality outcome.   
 
1.6.2 Analytical  
 
To address the aim and objective of this study, it was better to use an analytical tech-
nique; according to Joubert and Ehrlich (2007:78) an analytical study look details of fac-
tor associations (chapter 3 discusses in detail).  
 
1.6.3 Retrospective cohort 
  
An analytical cohort study aim at examining the possible relationship between an expo-
sure and an outcome (Joubert and Ehrlich 2007:79). The same authors also describe 
the existence of two types of cohort studies: prospective and retrospective. A prospec-
tive cohort is a study which the researcher studies and observes a population for a cer-
tain duration of time in a forward direction while a retrospective cohort study “shortens 
the time needed to conduct a cohort study as it makes use of historically or previously 
compiled data” (Joubert and Ehrlich 2007:81). The research is a retrospective cohort 
study design looking at the factors (clinical, laboratory, and treatment adherence) in re-
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lation to predictors of AIDS death retrospectively from patients’ records analysis. Odds 
ratio was calculated to indicate the strength of an association.  
 
1.7 RESEARCH METHODS 
 
The study was conducted in Gondar, Ethiopia; after ethical review approval was granted 
by the University of South Africa and Gondar University Hospital.  
 
1.7.1 Patients’ records and sample 
 
Data were drawn from all ART patients’ paper based medical records who have been 
on follow-up in GUH from 1 January 2007 to 30 June 2010. 
 
1.7.1.1 Study groups 
 
Record #1: Non survivors, ART patients’ records those who died during 1 January 2007 
– 30 June 2010. 
 
Record #2: Survivors, ART patients’ records those who were alive during 1 January 
2007 – 30 June 2010 and had follow-up at GUH ART clinic. 
 
1.7.1.2 Sampling method 
 
A systematic random sampling method was implemented for the survivor PLWHIV re-
cords. “In systematic sampling, individuals are selected at a fixed intervals from some 
list of ordering” (Joubert and Ehrlich 2007:100). In GUH, the ART registration log book 
has all the tracks of PLWHIV who have got service in the HIV clinic. To the end of June 
2010, the log book accounts for 8377 PLWHIV records to have ever been enrolled in 
the care; out of which 3370 were actively on regular follow-up. There were 2 information 
technicians who had been working in GUH I-TECH data room for assuring the com-
pleteness of the records before feeding the data to an electronic copy. For the purpose 
of this study therefore, the total confirmed clean records of 2622 PLWHIV charts indi-
cated as an active status with complete record documentation were enrolled. The paper 
charts corresponding to the records were extracted from the GUH main chart room us-
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ing their unique ART number and later all labelled with new serial numbers. In this case 
for the sample size of 800, the sampling interval was 3; therefore to determine the ran-
dom starting point one had to draw a random number within the first sampling intervals, 
then after every third record was selected to the study group. While revising GUH ART 
clinic I-TECH database, the total number of death records of PLWHIV while on ART fol-
low-up between 1 January 2007 to 30 June 2010 were 360 (GUH 2010) out of which 
324 were adults with age greater than 18. Out of 324 charts, only 200 had complete 
documentation of both ART intake and follow-up sheets. Moreover, hospital causes of 
deaths were appropriately documented by then treating physician. Therefore with a stat-
istician recommendation from GUH, the total 200 death charts were considered for the 
study by further assigning four survivors PLWHIV charts for every death record from the 
same sampling frame. The sample size was determined as follows. 
Record # 1: N= 200 
Record # 2: N= 800 
 
1.7.1.3 Criteria for eligibility / exclusion 
 
Inclusion criteria 
Record #1 and Record #2: Those with CD4 T lymphocyte counts < 200 cells/mm3 or 
those with WHO stage 3 and CD4 < 350 or WHO stage 4 were included. 
 
Record #1: ART patients’ records, for those who had follow-up at GUH ART clinic and 
died during 1 January 2007 – 30 June 2010, and the cause of death documented in the 
patients’ charts. 
 
Record #2: ART patients’ records, for those who had regular follow-up at GUH ART 
clinic during 1 January 2007 – 30 June 2010. 
 
Exclusion criteria 
 
Record #1: < 18 years of age, patients’ records on Pre-ART follow-up, ART patients’ 
records that had no documented cause of death, and women patients’ records that died 
while on short course ART for the purpose of prevention of mother-to-child-transmission 
(PMTCT) of HIV were excluded. 
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Record #2: < 18 years of age, patients’ records on Pre-ART follow-up, lost to follow-up 
(LTFU) patients’ records; drop out from follow-up patients’ records; and women patients’ 
records that started short course of ART for the purpose of PMTCT of HIV were all ex-
cluded. 
  
1.7.2 Data collection 
 
Ethiopian Ministry of Health (MOH), ART intake and follow-up format was used after 
modification and exclusion of the unnecessary variables for this study; then the data col-
lection format was pretested before implementation (Federal Ministry of Health 
2010).Paper based patients’ charts (including intake and follow-up documents) and the 
I-TECH ART database were assessed for a retrospective case record analysis of clini-
cal and laboratory findings. 
 
The variables included in the data collection instrument were: sex, age, date of HIV di-
agnosis, date of ART initiation, types of ART regimens; CD4 cell count, weight, haemo-
globin value, adherence to ART and OIs. For non survivors (dead patients) the cause of 
death was also included (Annexure C).Data was collected by the researcher. 
 
1.7.3 Data analysis 
 
Data analysis was done with the assistance of a bio-statistician from CDC; the statisti-
cian was also actively involved in sample size determination and data collection tool 
modification. Data was coded and entered in to Statistical Package for Social Science 
(SPSS) Version 16; Predictive Analytics Software, (PASW). Bivariate and multivariate 
analyses, odds ratio and P-test were used. 
 
1.8 DESIGN VALIDITIES AND RELIABILITIES 
 
1.8.1 Validity 
 
To ensure the research validity, the source population for both groups were all drawn 
from GUH ART clinic record pool. The survivor records were selected with systematic 
random sampling technique while the total cleaned records of deaths were enrolled. 
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Follow-up time frame for both groups was similar, moreover there was not be any re-
cord bias, because the data collection method was a full document retrospective case 
record analysis.    
 
1.8.2 Reliability 
 
In this research the death records were limited in number therefore to ensure the re-
search reliability, all PLWHIV death records who had complete chart documentation in 
their hospital records were considered; additionally four survivor patients’ records were 
selected for every death record (Joubert and Ehrlich  2007: 83) and CDC statistician 
recommendation. Fifty more charts were reviewed from the survivor patients’ records as 
a contingency plan to complete the sample size in case of any lost paper based patient 
charts occur. Data was collected using a modified Ethiopian national Ministry of Health 
HIV patients follow-up charts which was standardized, and the researcher collected the 
data. The collected data was crossed checked with I-TECH patient follow-up database. 
The cleaned data then entered in to a password protected Microsoft excel file, which 
later was fed into SPSS. 
 
1.9 ETHICAL CONSIDERATIONS 
 
Ethical clearance from both University of South Africa (UNISA) and Gondar University 
was secured before rolling out any part of the research activity (Annexure G and An-
nexure H). Moreover a support letter was also issued from the hospital’s medical direc-
tor to facilitate an easy access to patients’ medical records (Annexure F) (chapter three 
discusses in detail). 
 
1.10 CONCLUSIONS 
 
Chapter one gave orientation to the study. Background of the problem, aim of the study, 
significance of the study and definitions of key concepts were all addressed in detail. 
The chapter also highlighted the research design, methods and ethical considerations.  
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
The aim of this study was to define predictors of mortality among people living with hu-
man immunodeficiency virus (PLWHIV) at Gondar University Hospital (GUH) anti retro-
viral treatment (ART) clinic. According to the findings, the purpose was to develop a 
care plan. This chapter reviews relevant literatures from previous studies on factors as-
sociated with acquired immunodeficiency syndrome (AIDS) deaths. The scope of this 
literature review therefore was to synthesize evidence from text books, published re-
searches, scientific reports and other credible sources of scientific work done globally 
mainly on HIV/AIDS and ART issues. 
 
2.2 PURPOSE OF THE LITERATURE REVIEW  
 
Literature review is to ‘re-view’ or ‘further look’ at what has already been studied and 
published on a particular subject (Joubert & Ehrlich 2007:66). The purpose is to inform 
the researcher of what is already known about that specific subject of interest in making 
knowledge based choices about policy, practice, research direction and resource alloca-
tion (Chalmers 2003:575). 
 
In this review several sources were consulted including medical and research text-
books, latest publications of scientific journals, World Health Organization (WHO) publi-
cations and guidelines, United Nation (UN) agencies reports, the internet and several 
Ministry of Health (MOH) publications. 
 
2.3 OVERVIEW OF HIV 
 
HIV is a lenti virus from the member of retrovirus family incremented as a cause of AIDS 
(Weiss 1993:1273; Douek, Roederer and Koup 2009:471), which leads to a failure of 
the immune system and predisposes to different life-threatening opportunistic infections 
and malignancies. There are four means of HIV transmissions which are; unprotected 
sex, mother-to-child-transmission (perinatal transmission) including breast milk, con-
taminated body fluids, blood, blood products and organ donation, and contaminated 
needles. 
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HIV infects CD4+T cells from the human immune system which are macrophages, T-
helper cells and dendritic cells (Cunningham, Donaghy, Harman, Kim and Turville 
2010:524). There are two species of HIV: HIV-1 and HIV-2. HIV-1 is more virulent and 
infective (Gilbert, Mckeague, Eisen, Mulins, Guéye-Ndiaye, Mboup and Knaki 
2003:573), and it is the dominant cause of HIV infection globally. HIV-2 has low infectiv-
ity and is mainly distributed in West Africa (Reeves & Doms 2002:1253). There are dif-
ferent rate for different individuals progression of HIV to AIDS. Most will progress within 
an average of 10 years of HIV infection, though some progress much sooner and some 
will stay much longer (Buchbinder, Katz, Hessol, O’Malley and Holmberg 1994:1123; 
Time from HIV-1 2000:1131). To date there is no publicly available vaccine or cure for 
HIV or AIDS (Fighting the world’s 2010; Robb 2008:1857). 
 
2.3.1 Global HIV burden 
 
According to World Health Organization (WHO) 2009 global HIV/AIDS report for year 
2009; the number of people living with HIV in total was 33.3 million [31.4 million – 35.3 
million] out of which adults account for 30.8 million [29.2 million – 32.6 million]. Even 
though the trend for people newly infected with HIV decreased from 2001 to 2009, there 
were around 2.6 million people newly infected in 2009, with adults contributed 2.2 mil-
lion and children (<15 years) 370000 (WHO 2009). The report from Joint United Nations 
Programme on HIV/AIDS (UNAIDS) indicate annual AIDS related deaths worldwide is 
decreasing from 2.1 million [1.9 million – 2.3 million] in 2004 to 1.8 million [1.6 million – 
2.1 million] in 2009 (UNAIDS 2010).  
 
2.3.2 HIV burden in Sub-Saharan Africa 
 
UNAIDS in 2009 reported that, Sub-Saharan Africa embraced 22.5 million [20.9 – 24.2 
million] people living with HIV in making the adult (15 – 49 years) HIV prevalence to 
5.0% [4.7% - 5.2%]. Annually, 1.8 million [1.6 – 2.0 million] adults and children became 
newly infected with HIV. Moreover, there were 1.3 million [1.1 – 1.5 million] AIDS related 
deaths among adults and children (UNAIDS 2010). According to the same report the 
major means of HIV transmission was unprotected heterosexual intercourse (including 
paid sex) and vertical transmission of HIV to newborns and breast fed babies. From all 
the countries with HIV pandemic in the world, South Africa remains the largest in the 
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world with an estimate of 5.6 million [5.4 million – 5.8 million] people living with HIV in 
2009 (UNAIDS 2010). Epidemic in East Africa used to be very high but since 2000 it 
has been declining and stabilizing, where as in West Africa the HIV prevalence has 
been relatively low with an estimate at ≤ 2% (UNAIDS 2010).  
 
2.3.3 HIV burden in Ethiopia 
 
In 2009 Ethiopia had a total of 1,216,908 people living with HIV out of which 79,871 
were children (Ethiopia AIDS resource centre 2010a). According to the same report, na-
tional fact sheet 2010, new HIV infections per year in 2009 was 137,494 from which 
14,276 were children. Ethiopian adult (15 – 49 yrs) HIV prevalence in 2009 was 2.4% 
and incidence of HIV was 0.29%. These numbers add up to a significantly high mortality 
figure; in year 2009 the total AIDS deaths were recorded to be 28,073 of which 3,537 
were children. 
 
2.4 ANTI RETROVIRAL TREATMENT  
 
Although HIV infection cannot be cured, the advent of highly active antiretroviral therapy 
(HAART) has transformed HIV in to a chronic controllable condition. Management of 
PLWHIV include not only antiretroviral drugs, but also social and psychological care, 
prevention of opportunistic infections and prevention of transmission of HIV. There are 
five goals of therapy. First, the improvement of quality and expectancy of life related to 
the clinical goal of the treatment. Second, the greatest possible reduction in viral load 
for as long as possible; which is the virologic goal of ART. Third, the immunological goal 
expects both qualitative and quantitative improvement in immune reconstitution. The 
remaining two are therapeutic and epidemiologic goals. The former describe a rational 
sequencing of drugs in achieving the clinical, virologic and immunologic goals in main-
taining treatment options, limiting drug toxicity and facilitate adherence; which the later 
aimed to reduce HIV transmission (Bartlett, Gallant & Pham 2009 – 2010:71). 
 
Treatment regimens for HIV infection are complicated and require a long term commit-
ment to high levels of adherence. A combination of clinical assessment and laboratory 
marker data, including viral load and CD4 counts together with individual circumstances, 
should guide therapeutic decision making. Therefore, based on these facts many coun-
tries developed their own national ART guideline according to their particular circum-
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stances. There are few other internationally acknowledged ART guidelines which are 
currently in wide use all over the world; Department of Health and Human Service 
(DHHS) and Centre for Disease Control and prevention (CDC) ART guidelines from 
United States and World Health Organization (WHO) ART guideline, which uses differ-
ent assessment and criteria for initiation and lifelong provision of ART in different socio-
economic and geographic setups. So far the main determinants for initiating antiretrovi-
ral therapy in most patients are patient readiness and CD4 count, even though the cut 
off point is different for different setups (Bartlett et al 2009-2010:71). 
 
Treatment is initiated with a combination of drugs started simultaneously. The preferred 
regimen is two nucleoside reverse transcriptase inhibitors in combination with either a 
non-nucleoside reverse transcriptase or protease inhibitors. Patients may need to 
change therapy because of virological failure or drug side effect (WHO 2010a:22). 
 
2.4.1 Millennium Development Goals 
 
The Millennium Development Goals (MDGs) and targets came from the Millennium 
Declaration signed by 189 countries, including 147 head of states, in September 2000 in 
order for the goals to be met within 15 years, making the final year of achievement be-
ing 2015 (UN 2000). They were designed in a principle to strengthen partnership be-
tween developed and developing nations, as it is clearly put in the declaration “To cre-
ate an environment at the national and global levels alike which is conducive to devel-
opment and the elimination of poverty” (UN 2000). The MDGs are eight in number and 
each goal has its own targets and indicators for monitoring progress; it is worth mention-
ing the goals: 
 
Goal 1: Eradicate extreme poverty and hunger 
Goal 2: Achieve Universal primary education 
Goal 3: Promote gender equality and empower women 
Goal 4: Reduce child mortality 
Goal 5: Improve maternal health  
Goal 6: Combat HIV/AIDS, malaria and other disease 
Goal 7: Ensure environmental sustainability 
Goal 8: Develop a global partnership for development 
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According to the above MDGs, three out of eight are directly related to health issues 
and the rest five goals also have major indirect influence in public and global health. 
 
In the context of this dissertation; activities undertaken in goal number six (combat 
HIV/AIDS, malaria and other diseases), has a paramount significance. One of the indi-
cators for this goal is: the number of children orphaned by HIV/AIDS (UN 2000) which is 
directly related to the total HIV/AIDS associated adult deaths in PLWHIV. Similarly, the 
rest of the goals and targets are also interrelated and should be seen as a whole.  
 
2.4.2 Progress made in Ethiopia 
 
Ethiopia, after committing to the Millennium declaration with the MDGs in 2000, has be-
gun working toward the 2015 set goals. The ‘Millennium AIDS campaign’ designed by 
the federal government has been the centre piece of efforts to scale up prevention and 
treatment program. Moreover, Ethiopia joined the United Nations (UN) general assem-
bly in issuing the political declaration of HIV/AIDS in 2006 (Ethiopia MDGs 2010). In co-
operation with multiple stake holders, quality HIV/AIDS services have been delivered at 
the community level and in a context of task shifting approach from high level health 
professionals (General practitioners and Specialist doctors) to mid level health profes-
sionals (Nurses and Health officers), various standardized guidelines and trainings were 
developed, distributed and carried out (Ethiopia MDGs 2010). 
 
According to the 2010 Ethiopia MDGs report, with the above efforts in place, Ethiopia 
has been able to provide free ART for 206,907 PLWHIV in 2008 / 2009. Additionally, a 
trend analysis of HIV/AIDS prevalence rate shows that the urban epidemic appears to 
have levelled off at a higher prevalence in the past years while the rural epidemic hasn’t 
shown significant change (Ethiopia MDGs 2010). In the same report, there are an esti-
mated 1.1 million PLWHIV in Ethiopia with adult HIV prevalence in 2009/10 estimated to 
be 2.4% but HIV/AIDS incidence rate has remained below 0.3 percent. 
 
Overall the Ethiopia Ministry of Health focused its national response strategy in alleviat-
ing the HIV/AIDS burden in accordance to MDG 6 which is towards achieving a univer-
sal access focusing on three key approaches: the health extension program targeting in 
prevention and awareness creation support, health facility expansion in ensuring easy 
access to health facilities, and human resource capacity development. In the 2010 
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MDGs report, the Ethiopian Ministry of Health was enthusiastic about the progress on 
HIV/AIDS and malaria and the progress made is commendable. It is thus highly prob-
able that the MDGs target will be met in 2015.    
 
2.5 DEATH IN PEOPLE LIVING WITH HIV 
 
Globally, there has been a huge number of HIV/AIDS associated deaths and hence 
HIV/AIDS has remained one of the major health burdens in the world today. Developed 
versus developing countries differ significantly in the rank of the cause of death there-
fore a global summary are not adequately descriptive. However, to merely indicate 
some of the global facts: in 1998 HIV/AIDS ranked the fourth, as a major cause of death 
worldwide with a global total of 2,285,229 people (Cause of death 1998). In another re-
port from WHO in 2002, HIV/AIDS was incriminated as the number one cause of death 
in developing countries with the total death of 2,678,000 (List of causes 2002). Although 
both reports cited above are outdated due to the lack of recent data on these issues, 
one can learn the significance of the problem from the reports. HIV/AIDS associated 
deaths occur in both groups of PLWHIV, patients who have never been exposed to anti-
retroviral drugs, the so called ART naive and those patients who are on ART. In one 
study done in India, it is found that mortality was high among those not on HAART 
(81%) while it is significantly reduced (28%) among those on HAART (P < 0.001) (Ra-
jagopalan, Suchitra, Shet, Khan, Garcia, Nonnemacher, Jacobson and Wigdahl 
2009:219). 
 
2.5.1 Death while on Pre ART  
 
Symptom free ART naive or Pre ART PLWHIV are categorized in to two groups based 
on their CD4 count, high CD4 count and low CD4 count, according to WHO 2010 ART 
guideline which makes the cut-off CD4 level for the two groups to be at 350 cells/mm3 
(WHO 2010a:24). One recent study noted that ART naive patients with high CD4 cell 
counts death rates were raised compared with the general population, even though the 
finding was not in a strong statistical significance and can be due to confounding factors 
(Death rate in HIV-positive 2010:340). On the other hand, mortality rate is very high for 
those groups with CD4 counts of less than 350 cells / mm3, it has been indicated in dif-
ferent studies and therefore 350 cells/mm3 CD4 count is taken as a cut-off point for ini-
tiation of ART (WHO 2010a:24). 
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When one discusses mortality, it is also sound to look-up an overview about the causes 
of death. In one study, recurrent diarrhoea followed by pulmonary tuberculosis (TB) at 
first hospital admission of PLWHIV was found to be the major causes of death. In the 
same study, Pneumocystis Jiroveci Pneumonia (PCP), Cryptococcus meningitis and 
Toxoplasmosis were also found to negatively affect survival, even though the findings 
were not statistically significant (Rajagopalan et al 2009:219). From another study the 
leading cause of death appear to be tuberculosis, acute sepsis, cryptococcal meningitis, 
malignancy and wasting syndrome (Lawn, Harries, Anglaret, Myer and Wood 
2008:1897).  
 
Globally Mycobacterium tuberculosis is the leading cause of morbidity and mortality 
among PLWHIV. In Ethiopia there is a huge burden of co-infection rate of symptomatic 
HIV infection and tuberculosis which is reaching 20 – 50% (FHAPCO 2008:10). Accord-
ingly one can extrapolate tuberculosis as a major cause of death in the country. There-
fore from all of the cases above, one can clearly note that the causes of mortalities cor-
respond mainly to AIDS defining opportunistic infections.  
 
2.5.2 Death while on ART  
 
Following the introduction of HAART, the mortality rate among PLWHIV significantly de-
creased (Rajagopalan et al 2009:219; WHO 2010a:26). Despite this improvement, Sub-
Saharan Africa is still staggering with a very high mortality rate of between 8 and 25% of 
PLWHIV in the first years of initiation of ART (Lawn et al 2008:1897). From all global 
deaths that have occurred during ART, the highest death rate occurs in the first month 
of treatment, “Mortality declined by 9 fold after the 8th week of follow-up” (Jerene, En-
dale, Hailu and Lindtjorn 2006:136). Furthermore, a study mentions that the excess 
mortality in PLWHIV is moderated by the treatment and reaching the mortality rate of 
the healthy general population by the second year of ART (Brinkhof, Boulle, Weigel, 
Messou, Mathers, Orrell, Dabis, Pascoe and Egger 2009:e1000066). Similarly, a study 
from a rural hospital in Tanzania described that the majority of deaths occurred in 
PLWHIV who were initiated ART to be within the first three months of the therapy (Jo-
hannessen, Naman, Ngowi, Sandvik, Matee, Aglen, Gundersen and Bruun 2008:52). 
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The cause specific mortality of PLWHIV who were on ART is found to be mainly linked 
to an advanced HIV disease at treatment initiation (as reflected by low CD4 cell count) 
and immune reconstitution inflammatory syndrome (IRIS) (Journal watch 2009).  
 
2.6 ADHERENCE TO ANTIRETROVIRAL TREATMENT 
 
Adherence means a “faithful attachment”; “devotion” (THE FREE DICTIONARY 2011) 
therefore adherence to ART is devotion in proper taking of the antiretroviral drugs as 
prescribed by the health care providers. Federal Ministry of Health (2010) in Ethiopia 
described adherence in three distinct stages as good, fair or poor (Table 2.1). For 
HAART to be effective patients need to take > 95% of their prescribed tablets of antiret-
roviral drugs (Table 2.2). 
 
Table 2.1: Adherence to ARV drugs 
 
 % (of 30 doses) (of 60 doses) 
G (good) > 95 % <= 2 doses < 3 doses 
F (fair) 
85 – 94 % 3 – 5 doses 3 – 9 doses 
P (poor) < 85 % >= 6 doses > 9 doses 
Adopted: (Federal Ministry of Health 2010)   
 
Table 2.2: Correlation between adherence and virologic response to ART 
Adherence to ART Viral load < 400 copies/ml 
> 95% adherence 78% 
90 – 95% adherence 45% 
80 – 90% adherence 33% 
70 – 80% adherence 29% 
< 70% adherence 18% 
Adopted: (FHAPCO 2008:103) 
 
Multiple studies have confirmed the importance of adherence but in the real world it is a 
very difficult issue for PLWHIV to have adequate adhere all the time to the ART medica-
tions which are supposed to be taken life-long. In one secondary analysis of prospective 
clinical trial data in USA, differential adherence to ART drugs combination was reported 
at least once by 29% of participants over 60 months median follow-up time (Gardner, 
Sharma, Peng, Hullsick, Burman, MacArthur, Chesney, Teizak, Friedland and Mann-
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heimer 2008:75). Similarly in another retrospective data analysis of 4476 PLWHIV who 
are on ART in South Africa, 65% missed no visits, while 26% missed one visit, 7% 
missed two and 1.6% missed three or more visits during the first six months on treat-
ment (Brennan, Maskew, Sanne and Fox 2010:49).  
 
2.6.1 Reasons for non-adherence 
 
A qualitative study from Brazil describes different challenges to ART adherence by clas-
sifying them into three categories; difficulties related to social factors and life style of the 
population, difficulties which are directly related to the use of medication, and difficulties 
related to negative beliefs about the use of ART (Melchior, Nemes, Alencar and Bu-
challa 2007:41).There are other multiple reasons stated in different countries but all di-
rectly or indirectly line up to the above categories. 
 
2.6.1.1 Difficulties related to social factors and life styles 
 
According to Melchior, stigma to live with HIV/AIDS is an important barrier for adher-
ence to ART for many PLWHIV who relate strong need to hide the disease and use of 
medication. Other social factors such as the consumption of alcoholic beverages and 
use of drugs were incriminated as major barriers to adherence. Social drinking is a fre-
quent mentioned obstacle for adherence (Melchior et al 2007:42). Missing a scheduled 
visit and lack of disclosure of HIV status were associated with non adherence from a 
retrospective review in South Western Uganda (Bajunirwe, Arts, Tisch, King, Debanne 
and Sethi 2009:139).  
 
2.6.1.2 Difficulties related to negative beliefs about the use of ART 
 
Perceptions and opinions about medications such as “medicine is what kills”, “AZT is for 
cancer”, “too much medicine is bad for health”, “you need to take a break from the 
medicine”, and “medicine makes you drowsy and slow” are all reasons which pull back 
PLWHIV from properly adhering to their medications (Melchior et al 2007:42). 
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2.6.1.3 Difficulties directly related to the use of medication 
Drug side effects such as nausea, vomiting, headaches and diarrhoea are reasons di-
rectly related to non adherence moreover intolerance to the smell or taste of medica-
tions. Difficulty to dissolve or swallow and confusion about the interval between doses 
also contribute to poor adherence (Melchior et al 2007:42-45).  
 
2.6.2 Barriers for optimal ART adherence 
 
An article from Uganda’s experience mention barriers for optimal ART-adherence in re-
lation to long waiting times in the HIV clinic, the lack of privacy during counselling and 
medical check-ups in the HIV clinic, stigmatisation, inadequate treatment by support 
staffs, lack of sufficient social support, food shortage in households of PLWHIV and in-
ability financing transportation to come to visit the HIV clinic (Cornet & Koster 2008). 
Additionally, key informant interviews in South Africa report that mere denial of the exis-
tence of HIV or of one’s own positive status, use of traditional medicines, speaking a 
different local languages from health service providers, being away from home, per-
ceived severity of side effects, and feeling better on treatment (Dahab, Charalambous, 
Hamilton, Fielding, Kielmann, Churchyard and Grant 2008:63) were identified as a pro-
hibiting factors from adherence to treatment in different studies. As one can note from 
the cited evidence above, multiple social, cultural, economical, communication and reli-
gious factors play different roles in negatively affecting optimal adherence in PLWHIV 
who are on ART. 
 
2.6.3 Virologic Failure 
 
In Ethiopian ART guideline virological failure is a plasma viral load above 10000 cop-
ies/ml in duplicates after six months on ART (FHAPCO 2008:77), but in the new 2010 
WHO’s guideline a virological failure is defined as a persistent viral load above 5000 
copies/ml (WHO 2010a:48). Poor adherence or non adherence predicts virologic failure 
but not necessarily resistance (Bajunirwe et al 2009:139). From the previously men-
tioned study in USA, of those patients with differential adherence 30% reported it before 
initial virologic failure, which made them in an increased risk of initial virologic failure 
plus with antiretroviral resistance compared with participants without differential adher-
ence before initial virologic failure (Gardner et al 2008:75). Similarly from the study in 
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South Africa, patients who missed two and three or more medical visits had an in-
creased risk of death (Brennan et al 2010:49). Moreover, one retrospective cohort study 
from Uganda indicates that non adherence to ART was significantly associated with 
mortality in two mechanisms. The first is non-adherence leading to failure to suppress 
viral replications which increase HIV mutation resulting in drug resistance HIV strains. 
The second is non-adherence make HAART to lose capacity to prevent viral destruction 
of the cellular immune system which progress to a decline in CD4 cell count which in 
turn leads to a predisposition to opportunistic infections (Abaasa, Todd, Ekoru, Kaly-
ango, Levin, Odeke and Karamagi 2008:241). 
 
2.7 IMMUNO RECONSTITUTION INFLAMMATORY SYNDROME (IRIS)  
 
IRIS only occurs in a subset of PLWHIV after initiation of ART. The name is self ex-
planatory constituting two core components, immune reconstitution and inflammatory 
condition. The immune reconstitution is associated with the effect of HAART in killing 
the HIV which in many cases stimulate the redistribution of memory T cells and rapid 
restoration of pathogen specific immune response (Agmon-Levin, Elbirt and Sthoeger 
2008:439,476; Kestens, Seddiki and Bohjanen 2008:419). This is then followed by poor 
homeostatic control that promote exaggerated immunopathological response, especially 
if viable pathogen or pathogen debris are present at high concentration (Kestens et al 
2008:419) although the precise mechanism of IRIS is not well understood. This patho-
logical inflammatory response can present in a wide scale of clinical spectrums, from 
mimicking a mild acute inflammation to a severe opportunistic infections, malignancy, or 
even autoimmune disease (Agmon-Levin et al 2008:439,476). In one published litera-
ture review, it was indicated that IRIS resulted in paradoxical short term morbidity and 
even mortality (Shelburne, Montes and Hamill 2006:1094). On the contrary another co-
hort study from Uganda shows the contribution of IRIS to mortality was limited and in-
significant (Casteinuovo, Manabe, Kiragga, Kamya, Easterbrook and Kambugu 
2009:973). The commonest forms of IRIS are associated with mycobacterium infec-
tions, fungi, and herpes virus (Dhasmana, Dheda, Ravn, Wilkinson and Meinties 
2008:191).  
 
There are no laboratory tests or acceptable criteria’s for diagnosis of IRIS, which re-
mains a diagnosis of exclusion (Agmon-Levin et al 2008:439,476). Therefore in re-
source poor settings where the primary goal is to initiate HAART, IRIS may go unrecog-
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nised and have fatal consequence. To curtain such conditions there is a need for con-
trolled clinical trials regarding the prevention or treatment of IRIS to guide clinicians in 
their approach to this series common clinical condition. 
 
2.8 PREDICTORS OF HIV/AIDS ASSOCIATED MORTALITIES 
 
HAART resulted in 65% decline in mortality (Jerene, Nǣss and Lindtjorn 2006:10). 
However, still many more HIV/AIDS associated preventable deaths have continued to 
occur in the post ART era; especially the highest death rate being recorded in the first 
months of initiation of treatment (Jerene et al 2006:136). 
 
2.8.1 Poor resource settings 
 
Patients starting HAART in resource poor settings have an increased risk of mortality 
rate in the first months of therapy when compared with those in developed countries 
(ART-LINC 2006:817). Despite the immunologic and virologic response to ART, the 
numbers are similar for both high and low income countries (Lawn et al 2008:1897). 
Therefore, one can see that HAART alone without proper OI management and nutri-
tional support does not prevent mortality among PLWHIV (Rajagopalan et al 2009:219). 
There have been many efforts to predict HIV/AIDS associated mortalities before hap-
pening. As one cohort study from Ethiopia indicates, advanced clinical stage of HIV 
while starting ART, anaemia, low body weight and lack of cotrimoxazole preventive 
therapy are incriminated as independent predictors of mortality (Alemu & Sebastián 
2010: 5398). Similarly another cohort from Ethiopia also pointed out those HIV patients 
with WHO clinical stage 4 status and total lymphocyte count (TLC) <= 750/mcl are as 
independent predictors of death (Jerene et al 2006:136). With similar intension to pre-
dict mortality among PLWHIV who are on ART, many more studies tried to pin point a 
wide spectrum of clinical and laboratory findings; for the scope of this literature review it 
is worth mentioning the most vivid.   
 
There are two retrospective cohort studies from South Africa and Singapore which tried 
to predict mortality. The South African study indicates that the strongest predictors of 
mortality related to CD4 cell count < 50/µl, a haemoglobin concentration <= 8 g/dl, a his-
tory of oral candidiasis and a history of cryptococcal meningitis (Ojikutu, Zheng, Walen-
sky, Lu, Losina, Giddy and Freedberg 2008:204).  
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2.8.2 Malnutrition 
According to a study in Singapore, malnutrition at the time of starting ART is signifi-
cantly associated with decreased survival but the effect appeared not to be mediated by 
impaired immune reconstitution (Paton, Sangeetha, Earnest and Bellamy 2006:323). 
There are also three prospective cohort studies from Tanzania, Zambia and Senegal, 
each with their own version of mortality predictors. According to the Tanzanian’s cohort, 
anaemia, thrombocytopenia and severe malnutrition were strong independent predictors 
of mortality (Johannessen et al 2008:52), while from Zambia’s cohort, low serum phos-
phate at ART initiation was an independent predictor of early mortality among HIV pa-
tients starting ART with severe malnutrition or advanced immune-suppression (Heim-
burger, Koethe, Nyirenda, Bosire, Chiasera, Blevins, Munoz, Shepherd, Potter, Zulu, 
Taylor, Chi, Stringer and Kabagambe 2010:e10687).  
 
2.8.3 Opportunistic infections 
 
A cohort from Senegal indicated mycobacterium infections, neurotropic infections and 
septicaemia as the most frequent likely cause of death (Etard, Ndiaye, Mieg, Guéye, 
Guéye, Laniéce, Dieng, Diouf, Laurent, Mboup, Sow and Delaporte 2006:1181). There 
is also one case control study from India, which likewise came up with a finding that re-
current diarrhoea as a significant risk factor for mortality, followed by the diagnosis of 
pulmonary tuberculosis (TB) at first admission while TB in general also negatively im-
pact survival. In the same study WHO stage 4 AIDS defining clinical findings like Pneu-
mocystis jiroveci pneumonia, cryptococcal meningitis and toxoplasmosis also found to 
negatively affect survival, though the findings were not statistically significant (Ra-
jagopalan et al 2009:219). Furthermore according to Lawn (2008:1897), tuberculosis, 
acute sepsis, cryptococcal meningitis, malignancy and wasting syndrome were indi-
cated as the leading causes of death (Lawn et al 2008:1897). In many of the above 
studies TB is depicted as one of the major mortality predictors, but in one of the retro-
spective cohort study it is found that a history of TB in the contrary is not found to be a 
significant predictor of mortality (Ojikutu et al 2008:204).  
 
2.9 COMMON LIFE-THREATENING OPPORTUNISTIC INFECTIONS 
 
According to one retrospective study from Ethiopia, when ART is started for PLWHIV, 
immune restoration is paralleled with different opportunistic infections diagnosis, which 
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are tuberculosis (TB) (66.5%), toxoplasmosis (12.9%), herpes zoster rash (12.9%), 
Pneumocystis jiroveci pneumonia (4.1%) and cryptococcosis (3.5%) are all noted as 
immune restorative diseases (Huruy, Kassu, Mulu and Wondie 2010:46). In general, 
from opportunistic infections, milder infections occur early whereas series life-
threatening infections occur later with severe immunity failure. These lives threatening 
opportunistic infections are alternatively named as AIDS defining opportunistic infec-
tions (WHO 2010a:28). TB may occur early as well as later in HIV disease natural his-
tory but when TB occurs in a later advanced stage of AIDS, it is atypically more dis-
seminated and more extra pulmonary.  
 
2.9.1 Pulmonary Tuberculosis 
 
Mycobacterium tuberculosis is a causative agent for all kinds of tuberculosis infections 
(Bartlett et al 2009-2010:434). An estimated 1.37 million new cases of HIV-TB occurred 
in 2007, representing 15% of the total global burden of TB, 79% of TB-HIV diseases is 
in Sub-Saharan Africa, 29% of all cases in South Africa alone, TB is the main OI with 
23% of global HIV/AIDS mortality (Lawn and Churchyard 2009:325). According to the 
latest estimate, Ethiopia stands 7th in the list of high burden countries for TB, and half of 
the individuals who have active tuberculosis also have HIV co-infection (Federal Minis-
try of Health 2008:4). In the same report, the incidences of TB of all forms and smear 
positive TB stands at 378 and 163 per 100000 populations respectively. The prevalence 
and mortality of tuberculosis of all forms are estimated to be 546 and 73 per 100000 
populations respectively: in the year 2006/07 Ethiopia registered 129,743 cases of TB. 
 
At individual patient level HIV increases rate of TB reactivation by 100 fold (Chaisson 
and Martinson 2008:1089). HIV-TB co-infection alters clinical manifestation of TB, cre-
ates diagnostic challenges and complicates treatment. On the other hand TB also has 
an impact on HIV natural history. TB infection activates T-cells which indirectly supports 
HIV replication. Therefore active TB is associated with increased HIV-1 viral load, rate 
of progression to AIDS and mortality. Additionally TB therapy when combined with ART 
drugs has potential for serious drug-drug interaction and side effects. Tuberculosis can 
cause pulmonary and or extra pulmonary symptoms depending on the degree of im-
mune suppression. In patients with CD4 count below 200 cells / µl, tuberculosis is often 
atypical, with lower zone infiltration of the lung and tends to be extra pulmonary. Accord-
ing to a cohort study from Malawi, HIV increases the rate of recurrent tuberculosis by 
increasing the rate of re infection with mycobacterium tuberculosis bacteria, not as 
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cases of relapse from the previous TB disease (Crampin, Mwaungulu, Mwaungulu, 
Mwafulirwa, Munthali, Floyd, Fine and Glynn 2010:417). 
2.9.2 Toxoplasmosis 
 
CNS toxoplasmosis is caused by the protozoan parasite called Toxoplasma gondii 
(Bartlett et al 2009-2010:457). According to a cross sectional study in Ethiopia, the 
overall sero-prevalence of latent Toxo infection among the study subjects in Addis 
Ababa was 90.0%. Moreover, toxoplasma infection was observed with retrospective 
prevalence of 93.3% and 86.7% among HIV infected and HIV uninfected people 
(Shimelis, Tebeje, Tadesse, Tegbaru and Terefe 2009:213). The greatest risk is among 
patients with a CD4+T lymphocyte count < 50 cells / µl and almost exclusively related to 
reactivation of latent infection (FHAPCO 2008: 27). 
2.9.3 Pneumocystis Jirovecii Pneumonia 
 
The cause of pneumocystosis is a Pneumocystis Jirovecii fungal agent (Bartlett et al 
2009-2010:447). Pneumocystis jiroveci pneumonia (PCP) used to be considered as a 
reactive from a latent infection which was acquired in childhood but now it is believed to 
result from new infection from an exogenous source, and it causes fatal pneumonia in 
immune compromised individuals especially in AIDS patients (Herrag, Elfassy Fihry and  
Alaoul Yazidl 2010:342). Before the advent of HIV/AIDS, this disease used to be com-
mon in North America but it was less heard of in Africa including Ethiopia which is par-
tially associated with difficulty of definitive diagnosis or under reporting. In Ethiopia be-
cause of the definitive diagnosis difficulty, PCP among PLWHIV is diagnosed empiri-
cally for treatment (FHAPCO 2008:9). PCP has a huge seasonal variation in the inci-
dence and mortality rate, the highest mortality is in autumn (21.2%) and lowest in spring 
(9.7%), however the overall mortality rate is 13.5% (Miller, Evans, Copas, Huggett, Ed-
wards and Walzer 2010:497). 
 
2.9.4 Cryptococcus Meningitis 
 
HIV associated Cryptococcus infections mainly Cryptococcus meningitis is caused by 
Cryptococcus neoformans which is a fungal infection (Bartlett et al 2009-2010:404). 
One descriptive study from Ethiopia indicated, Cryptococcus meningitis is common 
among patients with immune suppression and with highest case fatality rate (Seboxa, 
Alemu, Assefa, Asefa and Diro 2010:237). Similarly another longitudinal study from 
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Cambodia also described cryptococcal meningitis as an important cause of morbidity 
and mortality in Cambodian HIV-infected patients (Espié, Pinoges, Balkan, Chanch-
haya, Molfino, Narom and Puiades-Rodriguez 2010:1375). 
2.10 SUMMARY 
 
Based on the evidence presented so far, one can easily note that there are long lists of 
mortality predictors in different countries. Accordingly, it is necessary to validate the 
studies with the countries real context before endorsing the raw evidence from different 
clinical setups. Additionally in Ethiopia, especially in North West part, where Gondar 
University Hospital accommodates the highest PLWHIV in its ART clinic: a recent and 
sufficiently exclusive data is in scares related to mortality predictors in PLWHIV who are 
on ART. Therefore, identifying and short listing strong mortality predictors will help to 
improve the survival of many HIV patients in evidence based clinical practice approach. 
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CHAPTER 3 
RESEARCH DESIGN AND METHOD 
 
3.1 INTRODUCTION 
 
Chapter two dealt with literature review related to previous research works and pub-
lished documents in the context of the topic under discussion. Here in chapter three the 
details of the research design, research methods, reliability, validity and ethical consid-
eration will be discussed. 
 
3.2 RESEARCH DESIGN 
 
Research design is a systematic general plan enabling the researcher to provide a solu-
tion to the research problem being studied, with minimum bias and scientifically sound 
result while addressing some research problems encountered during execution phase. 
In a broad sense “the research design is the architectural back bone of the study” (Polit 
and Beck 2008:66). A wide variety of research designs are available. For this research 
a quantitative, analytical, retrospective cohort study is used to address the research ob-
jectives by focusing on the research problem. The study took place in northwest Ethio-
pia, Amhara regional state, Gondar University Hospital ART clinic, Gondar. 
 
3.2.1 Quantitative study 
 
The theme of a quantitative study is finding a connection between concepts by defining 
relationships (cause and effect) among variables using different numeric statistical 
methods (Burns and Groove 2005: 747). Similarly another authors Stommel and Wills 
(2004:442) describe the use of numeric scales to measure the association between 
multitude of variables and outcome of interest, which can further be analyzed statisti-
cally and produce scientifically sound relationships. 
 
This research revised selected laboratory and clinical histories of the study population 
using the data collection tool in reaching to an important association between the differ-
ent variables and the cause of death to predict the occurrence of mortality ahead of time 
in PLWHIV who were on ART. 
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3.2.2 Analytical study 
  
According to Joubert and Ehrlich (2007:78), an analytical study will address to find the 
factors that predict an outcome of interest by looking deep into associations and rela-
tions of factors rather than simply describing how much the outcome of interest present. 
 
This study analyzed the different variables independently by grouping and sub-grouping 
to come up with predictors of mortality from the observed variables. Using analytical 
method for this research brought to light overlooked factors which have statistical or 
clinical significance in predicting mortality for PLWHIV who were on ART. 
 
3.2.3 Cohort study 
 
A study design also needs to include the number of times in which data will be col-
lected. A study involving the collection of data more than one point in time over an ex-
tended period is a longitudinal design, whereas a study in which data are collected once 
in order to capture the phenomena under study is a cross sectional design (Polit and 
Beck 2008:208).  
 
A cohort study also known as a follow-up or longitudinal study encompasses three main 
points: a group of people, certain common characteristic and follow-up time. Therefore 
the relationship between an exposure and an outcome in the followed groups of people 
over a certain given time can be examined (Joubert and Ehrlich 2007:79). The same 
authors also describe the existence of two types of cohort studies: prospective and ret-
rospective cohort. Time is an important factor for either retrospective or prospective de-
signs, timing refers to the occurrence sequence of independent and dependent vari-
ables but not timing of data collection (Polit and Beck 2008:210). 
 
3.2.3.1 Prospective cohort study 
 
A prospective cohort is a study which the researcher selects the study population at the 
beginning of the study period and follows them in a forward direction through the calen-
dar time and eventually record whether the outcome of interest develop or not (Joubert 
and Ehrlich 2007:81). A prospective longitudinal cohort study is important for studying 
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the dynamics of phenomena over time in which data are collected at more than one 
point in time with an extended follow-up of the cohort groups (Polit and Beck 2008:210).  
 
3.2.3.2 Retrospective cohort study 
 
Retrospective cohort, the name is self descriptive; the study has a backward direction 
and the acquisition of data is retrospectively from past records (Kirkwood 1994:156). It 
“shortens the time needed to conduct a cohort study as it makes use of historically or 
previously compiled data” (Joubert and Ehrlich 2007:81). Retrospective studies are typi-
cally cross-sectional in nature, data inferred all about the variables and events occurred 
in the past are collected at a single point in time (Polit and Beck 2008:210).  
 
In this research data from antecedents or determinants occurring in the past were col-
lected at a fixed point in time with a cross-sectional fashion, from a cohort of HIV pa-
tients who started ART at GUH during January 01, 2007 and June 30, 2010. These co-
horts of HIV patients’ charts farther subdivided in to two groups: survivor PLWHIV 
charts and dead HIV patients’ charts. In-sum the study helped to look at the variables 
(clinical, laboratory and treatment adherence) in relation to AIDS associated deaths ret-
rospectively from the corresponding GUH paper based patients’ records. 
 
3.2.3.3 Strength of a cohort study 
 
In cohort studies one can certainly know that the exposure precedes the outcome of in-
terest, which is one of the criteria helping to claim a causal relationship between a factor 
and an outcome. Additionally, the researcher can assess a range of outcomes in rela-
tion to the variables being studied (Joubert and Ehrlich 2007:81). Therefore if one con-
ducts a research, the strength of evidence collected by a cohort study is stronger than 
the rest of the observational studies. 
 
3.2.3.4 Limitations of a cohort study 
 
In cohort studies, after data collection, the analysis is complicated. Sometimes in a very 
long prospective cohort studies adjustments need to be considered for the possible ag-
ing of the study groups. In addition cohort studies bear different logistic problems and 
become costly (Kirkwood 1994:156). Cohort studies are also vulnerable to biases; in a 
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prospective cohort: loss to follow-up of participants and reporting of outcome by the par-
ticipants; in retrospective cohort: incomplete or lost documentations, may contribute in 
introducing information bias to the studies (Joubert and Ehrlich 2007:82). 
 
3.3 RESEARCH METHOD 
 
According to Polit and Beck (2008:765) research method is “the technique used to 
structure a study and to gather and analyze information in a systematic fashion”. In the 
methodology portion of a research, one can look at details of the study population, 
sampling techniques, data collection instruments, data collection approaches and meth-
ods.  
 
3.3.1 Study population 
 
The study population is a group whose members have certain common attributes about 
which the researcher wants to gather information and draw conclusion. The population 
do not always have to be people, rather events, places, objects and animals can make 
up a study group; additionally study population should have clear description in respect 
to place, time and other factors relevant to the study (Joubert and Ehrlich 2007:94). Ac-
cording to Stommel and Wills (2004:297) in conducting a research, population are de-
scribed as, target population and accessible population. Target population are the ideal 
full set of population with a character of interest in which the researcher wants to project 
the study findings for generalization. In this study the target population were all PLWHIV 
in Ethiopia who were on ART. Whereas the accessible population are subsets of the 
target population from which a representative sample or the whole population are actu-
ally subjected to the research. In this study the accessible population were all PLWHIV 
in Ethiopia who were on ART and more specifically whose ART initiation and subse-
quent follow-up was located in GUH ART clinic. Inclusion and exclusion criteria’s are 
considered as very important components of the study population which will help to 
screen those who will participate in the study (Joubert and Ehrlich 2007:94). 
 
3.3.2 Screening tool 
 
The clinical factors for the accessible population were those patients’ charts with initial 
‘CD4 T lymphocyte count < 200 cells/mm3’ or those with ‘WHO stage 3 and CD4 < 350 
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cells/mm3’ or ‘WHO stage 4’, because these are the eligible PLWHIV who can start ART 
in Ethiopia. The other important factor here was that the charts need to have full and 
proper documentations including in-hospital documentation of the cause of death for the 
dead patients’ charts. The exclusion criteria’s for this study were age less than 18 years, 
patients’ records for those on pre-ART follow-up and women patients’ records who died 
while on short course ART for the purpose of prevention of mother-to-child-transmission 
(PMTCT) of HIV. 
 
3.3.3 Sampling 
 
Sampling is the process of selecting individuals from a population who will be studied 
(Burns and Groove 2005:341). A sample needs to be representative of the study popu-
lation so that a researcher can generate the necessary information cost effectively 
(Joubert and Ehrlich 2007:94). There are two major types of sampling methods: ran-
dom/probability sampling and non probability sampling. The former was of the principle 
that whether or not an individual is selected depends upon chance, whereas the later 
sampling technique depends on the researcher role in determining for an individual se-
lection (Joubert and Ehrlich 2007:95). Similarly Polit and Beck (2008:762,764) define 
probability sampling as “the selection of sampling units (e.g., participants) from a popu-
lation using random procedures (e.g., simple random sampling or cluster sampling)” and 
random sampling as “the selection of a sample such that each member of a population 
has an equal probability of being included”. Probability sampling ensures representa-
tiveness of the probability sample, hence it is the most preferred and respected method 
of the two approaches (Polit and Beck 2008:340). To perform random sampling, a sam-
pling frame is needed which is a full list of members of the population from which the 
study participants (sampling unites) will be selected (De Vos, Strydom, Fouche and 
Delport 2007:194).  
 
There are different types of random sampling techniques: simple random sampling, 
stratified random sampling, cluster sampling and systematic sampling (Polit and Beck 
2008:344-348); from those “systematic random sampling is particularly useful if a sam-
ple of patient records has to be selected” (Joubert and Ehrlich 2007:100). To perform 
systematic random sampling, the study frame need to be listed down orderly and with 
the first participant chosen at random, the rest will be selected at a fixed sampling inter-
val. 
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In this research a systematic random sampling method was implemented for all survivor 
PLWHIV chart records. In GUH, the ART registration log book had all the tracks of 
PLWHIV who have got services in the ART clinic. According to the ART clinic log book, 
up to the end of June 2010 there were 8377 PLWHIV records that have ever enrolled in 
care; out of which 3370 were actively on regular follow-up. Out of the 3370 active 
PLWHIV only 2622 had a follow-up period between January 01, 2007 to June 30, 2010 
with clean and complete paper based chart records; and their clinical information were 
also fully transferred to an electronic database. Therefore, the 2622 paper based 
PLWHIV chart records were taken as a study frame. The charts were extracted from 
GUH main chart room using their unique ART numbers and later all were labelled with a 
new serial numbers. According to a statistician’s recommendation a sample size was 
determined to be 800. Therefore, to come-up with the 800 sample size of survivor 
PLWHIV charts, one needs to divide 2622 by 800 to reach for the sampling interval: 
which is 3.28 (approximate to a whole number ‘3’). Thereafter to determine the random 
starting point, the research had drawn a random number within the first sampling inter-
val so that every third record was selected to the study group. 
 
While revising GUH ART clinic I-TECH database, the total number of death records of 
patients who once had ART follow-up at the hospital’s ART clinic between January 01, 
2007 to June 30, 2010 were 360 (GUH 2010); out of which 324 were adults with age 
greater than 18. From the 324 charts only 200 had complete documentations of ART 
intake sheets, follow-up sheet and hospital cause of death. Therefore, again at the stat-
istician’s recommendation, the total 200 dead patients’ paper based charts with a com-
plete documentation were included in this study. 
 
3.3.4 Sampling error 
 
Polit and Beck (2008:765) defines sampling error as “the fluctuation of the value of a 
statistic from one sample to another drawn from the same population”; which in other 
words indicate the discrepancy between a true population result and a sample result. 
There is always a big concern among researchers over whether a sample value reliably 
estimate true population parameter; in this respect probability sampling allows re-
searchers to estimate the magnitude of sampling error (Polit and Beck 2008:348).   
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3.3.5 Research assistant 
 
Data collection was done by the researcher, who is a medical doctor and has worked as 
HIV physician for more than 4 years, specially the recent 2 years at GUH as a physician 
mentor in the ART clinic where the research took place.    
 
In GUH there were two full time information technicians who were employed by I-TECH 
as a technical assistance in supporting the ART clinic data room for assuring the com-
pleteness of the paper based patients’ records before feeding the data into an electronic 
database. They were requested to be involved in this research to help list down and or-
der the paper based charts unique ART number during their off duty hours. Following, a 
porter from GUH ART clinic was also requested to assist in collecting the paper based 
charts from the main chart room similarly on his off duty hours. Special training about 
the research was not considered for the assistances, as they were not involved in any-
ways with the technical aspects of the research apart from an extra work load in their 
routine activities. For all the assistants’ stipend was paid as individual mutual agree-
ment. 
 
3.3.6 Data collection approach and method 
 
The format and variables of the data collection instrument had two sections, demo-
graphic and clinical follow-up characteristics that correspond to the regular GUH ART 
clinic patient intake and follow-up form. Therefore it was simply be the transferring of 
information with the corresponding variables. In case of information’s were misplaced or 
written in different parts of the chart, the data collector dug the information from the 
chart review and transferred the findings to the correct variable locations in the data col-
lection instrument. Overall meticulous chart review was performed for inclusion of all the 
necessary variables. For ambiguous and illegible handwriting, GUH I-TECH ART elec-
tronic database was consulted.   
3.3.7 Data collection instrument 
 
The Federal Ministry of Health, Ethiopia, HIV care/ART follow-up form has been used 
universally throughout the country as a paper based chart for HIV clinic clients to docu-
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ment all issues related to HIV/AIDS, opportunistic infections and ART (Annexure D).  
Therefore, for the purpose of this research only selective variables of high interest were 
incorporated from the follow-up form in to the data collection tool to address the re-
search problem and objectives. The items directly transferred in the data collection tool 
were (Facility name, Age, Sex, Date confirmed HIV +, Eligible date, Eligible and ready 
date, Follow-up date, Opportunistic infections, Weight in kilogram, Functional status, 
WHO stage, ARV drugs, Adherence, Side effect, Reason for change of drug, CD4/mm3 
and Haemoglobin count). There were two modified items (Number and Patients’ resi-
dence); “Number” was allocated by the researcher sequentially corresponding to their 
unique ART numbers in the client’s follow-up form whereas “patients’ residence” was 
broadly categorised as “Gondar town” residence or “outside of Gondar” residence refer-
ring to the clients’ complete address from their follow-up form. There were two items 
added by the researcher: the current status of patients “alive” or “dead” and for the dead 
groups “the cause of death”. The values for all these variables were easily found during 
the chart review data collection period either directly from the ART follow-up form or 
from the paper based client’s general hospital chart. The data collection tool was de-
signed by the researcher in collaboration with a statistician. The tool has two portions; 
the upper most part which concentrates on demographic data including HIV confirmed 
date, eligibility and readiness date for the initiation of ART. 
 
 The second and lower portion incorporated the patients’ follow-up status, encounters of 
opportunistic infections, weight, functional status, ART adherence, ART drug types, 
ART drug side effect, and reasons for changing ART drugs; finally the laboratory inves-
tigation values which have a direct relationship with HIV treatment outcome and side 
effect: CD4+ cell count and haemoglobin (Annexure C). The data collection instrument 
was pretested in a randomly selected 50 charts from GUH ART clinic before implemen-
tation.   
 
3.3.8 Data analysis 
 
Data analysis is a process carried out at the completion of the data collection; which will 
categorize, put in order, manipulate and summarize the data in order to be able to an-
swer the research problem, in the mean time addressing the aim of the research (De 
Vos et al 2007:218). For this research, the statistician assistance was paramount in 
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analyzing the collected data. Moreover proper cleaning procedures were performed be-
fore coding and entry of the data in to SPSS version 16 statistical software for analysis. 
 
Using SPSS, bivariate and multivariate analysis were performed for association be-
tween variables and mortality. Odds ratios (ORs) were derived from the bivariate and 
multivariate analysis. Finally a two sided statistical significance test were carried out 
with a probability cut-off value of 0.05.  
 
3.4 RELIABILITY AND VALIDITY 
 
Reliability, precision and repeatability can interchangeably be used to describe the 
same character. Likewise validity and accuracy can also be used interchangeably; but it 
is important to give attention to the fact that reliability and validity (or their inverse, im-
precision and bias) are different phenomena, therefore they need to be discussed sepa-
rately (Joubert and Ehrlich 2007:156). 
 
3.4.1 Reliability 
 
Reliability or precision refers to stability, consistency, repeatability or reproducibility of 
the measurements; if the measurements were taken over and over again, it provides an 
indication of the random error in the measurement (Burns and Groove 2005:374; 
Joubert and Ehrlich 2007:155). In this study all complete charts of the dead and almost 
one out of three alive PLWHIV charts were enrolled in the study making the total study 
population to be 1000. Therefore the larger the sample size in this study contributed to 
an increase in the precision of the study result. 
 
3.4.2 Validity 
 
Validity or accuracy is the proximity of a measurement to the truth (Joubert and Ehrlich 
2007:156). The same author in another context describe validity as “the extent to which 
a measurement instrument actually measures what it is meant to measure” (Joubert and 
Ehrlich 2007:117). According to Burns and Groove (2005:214) validity is a “measure of 
the truth or accuracy of a claim”. 
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In this research to ensure the research validity, the source population for the dead and 
alive HIV patients was all drawn from GUH ART clinic record pool that had similar crite-
ria of treatment initiation with the same enrolment study duration. The survivor PLWHIV 
medical records were selected with a systematic random sampling technique while the 
total cleaned and completed records of the dead HIV patients’ charts were all enrolled in 
this study. There was no record bias, because the data collection method was a full 
document retrospective case record review and analysis. In a broad context, clinical at-
tendees were not representative of the general population since those who attend the 
clinic in some way differ from other community members who did not. However, in this 
particular study, the all the study population need to visit the ART clinic to have ART 
exposure; therefore this possible bias had no place to interfere with this research. 
 
3.5 ETHICAL CONSIDERATION 
 
According to the American heritage dictionary (2000) ‘ethics’ is defined as “a theory of a 
system of moral values”, “the study of the general nature of morals and of the specific 
moral choices to be made by a person” and “the rules or standards governing the con-
duct of a person or the members of a profession”. 
 
Respecting to the above ethical values, there were many considerations taken while 
conducting this research. Initially the research proposal was submitted to UNISA Health 
Studies Research and Ethics Committee College of Human Sciences, from where a 
clearance certificate was granted for this project number: 4323-288-4. 
 
The clearance from UNISA, the research proposal, a request for wavier of consent and 
support letter from GUH Medical Director was then presented to Gondar University ethi-
cal review board for permission to conduct the study.  A one year ethical clearance cer-
tificate was granted. The request for waiver of consent to conduct the study, letter of 
support from GUH Medical Director, ethical clearance certificate from UNISA and Gon-
dar University are all annexed as annexure E, F, G and H respectively.  
 
Risk: There was no psychological or physiological risk with respect to this study. As 
there was no patient encounter or contact, the only approach was retrospective chart 
reviews which bear negligible risk. 
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Confidentiality: The subjects’ “unique ART number” was not collected in the process. 
Data was stored in an electronic copy in a password protected file on the investigator’s 
personal computer and backed-up in hard copy which was stored in a locked cabinet in 
a locked room. After completion of the study, the stored data won’t include any personal 
identifiers, and was not shared with government agencies or NGOs. 
 
3.6 CONCLUSION 
 
The chapter addressed the study design and method. The rationales for the selection of 
these specific study design and method were guided by different factors. These factors 
were: addressing the research problem efficiently, availability of data, ethical values, 
ability to control likely biases and the cost to conduct the study. The next chapter deals 
with the study results. 
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CHAPTER 4 
ANALYSIS, PRESENTATION AND DESCRIPTION OF  
THE RESEARCH FINDING 
 
4.1 INTRODUCTION 
 
Chapter 3 described the research design and method, which is quantitative, analytical, 
retrospective cohort study on predictors of mortality among human immunodeficiency 
virus infected patients’ records in Gondar University Hospital-Ethiopia. The aim of the 
study was to define predictors of mortality among PLWHIV at GUH ART clinic. In this 
chapter; analysis, presentation and description of the research findings are discussed. 
 
4.2 DATA MANAGEMENT AND ANALYSIS 
 
The data collection tool was structured in two sections as follows: 
 Demographic characteristics 
 Patient follow-up history 
Data from the data collection instrument was coded on the summary sheets by the re-
searcher. The data was then analysed and interpreted with the great help of a biostatis-
tician using the Statistical Package for Social Scientists (SPSS) and Microsoft Excel 
computer programs. The study findings were then presented in a narrative format, ta-
bles and diagrams to further clarify the relationships of the different variables and find-
ings. 
 
4.3 RESEARCH RESULTS 
 
The following is the presentation of the research results. 
4.3.1 Sample characteristics (N=1000) 
 
The sample frame for the study consisted of charts of PLWHIV who were on ART and 
had a regular follow-up at GUH ART clinic from 1 January 2007 to 30 June 2010. These 
charts were further categorised in two groups: dead and alive (Alive N=800 and Dead 
N=200). The study analysed both sexes of age 18 and above years. Charts of Women 
who started ART for the purpose of Prevention of Mother-to-Child-Transmission 
(PMTCT) of HIV were not enrolled in the sample. 
. 
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4.3.1.1 Sex 
 
From the total of 1000 reviewed HIV patients’ charts n=536 (53.6%) were females 
[(41.4%) were alive and the rest (12.2%) were dead]. Similarly there were n=464 
(46.4%) male patients’ charts reviewed; [(38.6%) were alive and n=78 (7.8%) were 
dead] by the end of June 2010. Table 4.1 and Figure 4.1 show the details of their sex 
distribution. In a bivariate analysis there was a correlation between mortality and Fe-
male sex, from the dead HIV patients n=122 (61%) were females, whereas n=78 (39%) 
of the dead patients were males therefore having a female sex was one of the predic-
tors of mortality (OR 1.458, 95% CI 1.063 – 2.001, P = 0.019); similarly in multivariate 
analysis female sex was also found to be one of the predictors of mortality (OR 1.748, 
95% CI 1.127 – 2.71, P= 0.013). 
  
Table 4.1: Sex distribution in the chart review of HIV patients who were on ART follow-
up at GUH from 1January 2007 – 30 June 2010 
  
   Bio status of the pa-
tients 
Total    alive Dead 
Sex of the pa-
tient 
male Count 386 78 464 
% within Sex of the patient 83.2% 16.8% 100.0% 
% within Bio status of the pa-
tients 48.2% 39.0% 46.4% 
% of Total 38.6% 7.8% 46.4% 
female Count 414 122 536 
% within Sex of the patient 77.2% 22.8% 100.0% 
% within Bio status of the pa-
tients 51.8% 61.0% 53.6% 
% of Total 41.4% 12.2% 53.6% 
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Figure 4.1: Sex distribution in the dead and alive HIV patients; GUH ART clinic patients 
chart review 
 
4.3.1.2 Age 
 
The mode of the patients’ age from the chart review was 23 years, but when one groups 
the age in such a way as age range: 18 – 25 years, 26 – 49 years and ≥50 years, the 
mode become the age range between 26 – 49 years. The mean age of the patients’ 
was 33.5 years and the median age was 32 years. According to the reviewed charts, 
the minimum age of the patient was 19 years and the maximum age of the patient was 
78 years old. From the total reviewed charts, n=248 (24.8%) alive and n=21 (2.1%) 
dead patients were in an age range of 18 – 25 years. The majority n=512 (51.2%) alive 
and n=151 (15.1%) dead patients’ charts fall in the age range between 26 – 49 years. 
Similarly in the age range above 50 years, there were only n=40 (4%) alive and n=28 
(2.8%) dead patients. Table 4.2 and Figure 4.2 show the detail of their age categories. 
None of the age group categories were significant indicators of mortality in the bivariate 
analysis. 
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Table 4.2: Age group distributions from the chart review of HIV patients who were on 
ART follow-up from 1 January 2007 - 30 June 2010 at GUH. 
 
   Bio status of the pa-
tients 
Total    alive Dead 
age of the patient 
grouped 
<=25 Count 248 21 269 
% within age of the 
patient grouped 92.2% 7.8% 100.0% 
% within Bio status of 
the patients 31.0% 10.5% 26.9% 
% of Total 24.8% 2.1% 26.9% 
26-49 Count 512 151 663 
% within age of the 
patient grouped 77.2% 22.8% 100.0% 
% within Bio status of 
the patients 64.0% 75.5% 66.3% 
% of Total 51.2% 15.1% 66.3% 
>=50 Count 40 28 68 
% within age of the 
patient grouped 58.8% 41.2% 100.0% 
% within Bio status of 
the patients 5.0% 14.0% 6.8% 
% of Total 4.0% 2.8% 6.8% 
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Figure 4.2: Age distribution in the dead and alive HIV patients; GUH ART clinic patients 
chart review 
 
4.3.1.3 Status of the patient 
 
Out of the reviewed 1000 charts, n=800 (80%) of them were charts of patients who 
were on ART follow-up at GUH between 1 January 2007 and 30 June 2010, and they 
were alive at the end of June 2010. The rest n=200 (20%) of them were charts of HIV 
patients who had follow-up at GUH between 1 January 2007 and 30 June 2010, but 
they were dead before the end of June 2010 while on treatment.  
 
4.3.2 Follow-up history 
 
During the chart review, patients’ ART follow-up history was given major emphasis. 
There were two laboratory and three clinical characteristics considered to be the area of 
interest in this study. The laboratory history noted the latest values of the patients’ CD4 
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cells and haemoglobin counts, whereas the clinical history focused on the history of Tu-
berculosis (TB), Oral Candidiasis and Cryptococcus Meningitis. For the clinical history, 
only the confirmed diagnoses were included in the study.  
 
4.3.2.1 CD4 count 
 
In Gondar University Hospital ART laboratory, HIV patients CD4 cell count had been 
determined every six months. The machine which determined the CD4 cell count was 
Fluorescent Activated Cell Sorter – Count (FACS-Count) from Becton Dickinson Com-
pany. The result from the chart review showed that the mean CD4 count was 152.65 
(153/µl) (standard deviation (SD) 78.9) and the median CD4 cell count was 172/µl (25th 
– 75th quartile = 91 – 209/µl). One hundred seventy four (17.4%) had the latest CD4 cell 
count ≤ 50/µl, five hundred fourteen (51.4%) a CD4 cell count of 51 – 199/µl and three 
hundred twelve (31.2%) a count of ≥ 200/µl; the detail can be seen in Table 4.3 and 
Figure 4.3.  
 
Out of the reviewed 200 dead HIV patient charts, n=134 (77%) had CD4 ≤ 50/µl; the 
rest n=60 (11.7%) had CD4 range 51 – 199/µl and n=6 (1.9%) had CD4 ≥ 200/µl. 
Bivariate analysis revealed that the most recent CD4 count ≤ 50/µl was a significant 
predictor of mortality (OR 170.85, 95% CI 70.74 – 412.63, P < 0.0001) (Table 4.4). Pa-
tients who died while on ART had a mean recent CD4 count of 57/µl compared with 
176/µl for those who were alive at the end on the study (June 2010). In multivariate 
analysis, patients with a CD4 count ≤ 50/µl had higher risk of mortality (OR 155.8, 95% 
CI 53.57 – 453.16, P<0.0001).  
 
The latest CD4 cell count range of 51 – 199/µl was also found to be one of the mortality 
predictors in the bivariate analysis (OR 6.74, 95% CI 2.876 – 15.795, P < 0.0001); tak-
ing this result in to the multivariate analysis similar result was also found with (OR 7.07, 
95% CI 2.975 – 16.8, P < 0.0001).   
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Table 4.3: CD4 groups distribution from the chart review of HIV patients who were on 
ART follow-up from 1 January 2007 to 30 June 2010 at GUH.  
     
   Bio status of the pa-
tients 
Total    alive Dead 
CD4 count 
grouped 
<=50 Count 40 134 174 
% within CD4 count 
grouped 
23.0% 77.0% 100.0% 
% within Bio status of 
the patients 
5.0% 67.0% 17.4% 
51-199 Count 454 60 514 
% within CD4 count 
grouped 
88.3% 11.7% 100.0% 
% within Bio status of 
the patients 
56.8% 30.0% 51.4% 
>=200 Count 306 6 312 
% within CD4 count 
grouped 
98.1% 1.9% 100.0% 
% within Bio status of 
the patients 
38.2% 3.0% 31.2% 
Total Count 800 200 1000 
% within CD4 count 
grouped 
80.0% 20.0% 100.0% 
% within Bio status of 
the patients 
100.0% 100.0% 100.0% 
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Table 4.4: Bivariate analysis of CD4 count and Bio-status of the patients 
 
  
B S.E. Wald df Sig. Exp(B) 
95.0% CI for EXP(B) 
  Lower Upper 
Step 1a cd4_grp   256.303 2 .000    
cd4_grp(1) 5.141 .450 130.573 1 .000 170.850 70.741 412.628 
cd4_grp(2) 1.908 .435 19.283 1 .000 6.740 2.876 15.795 
Constant -3.932 .412 90.972 1 .000 .020   
      
 
Figure 4.3: CD4 group distribution in the dead and alive HIV patients; GUH ART clinic 
patients chart review 
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4.3.2.2 Haemoglobin count 
 
In Gondar University Hospital ART laboratory, HIV patients’ haemoglobin count had 
been determined every six month together with their CD4 cell count. For patients who 
took Zidovudine (AZT) based regimen, which is a nucleoside analogue reverse tran-
scriptase inhibitors (NRTI), one of the drug found in the first line regimen of highly active 
antiretroviral treatment (HAART) combinations; haemoglobin count had been mandato-
rily determined every month for the first six months then after every six months similar to 
the rest of the drugs. The exception here is because, AZT is associated with anaemia. 
The machine which determined the haemoglobin count was Cell-Dyn 1800 from Abbott 
Company. 
 
The result from the chart review showed the mean haemoglobin count was 11.068 g/dl 
(Standard error of the mean (SE) 0.0587) and the median haemoglobin count was 11.9 
g/dl (25th – 75th quartile= 10.1 – 12.3). Out of the reviewed 1000 charts the minimum 
haemoglobin value was 4.6 g/dl and the maximum was 14.0 g/dl.  109 (10.9%) had the 
latest haemoglobin determined value of ≤ 8 g/dl, 891 (89.1%) a haemoglobin count of 
>8 g/dl: the detailed can be seen in Table 4.5 and Figure 4.4.  
 
Out of the reviewed 200 dead HIV patients’ charts, n=76 (38%) had haemoglobin count 
≤ 8 g/dl; the rest n=124 (62%) had haemoglobin > 8 g/dl. Bivariate analysis revealed 
that a recently determined haemoglobin count of ≤ 8 g/dl was found to be predictive of 
mortality (OR 14.245, 95% CI 9.079 – 22.352, P < 0.0001) (Table 4.5, 4.6 and Figure 
4.4). Patients who died while on ART had a mean recent haemoglobin count of 9.43 g/dl 
compared with 11.48 g/dl for those who were alive at the end of the study (June 2010). 
In multivariate analysis haemoglobin count was not significant. 
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Table 4.5: Haemoglobin count groups distribution from the chart review of HIV patients 
who were on ART follow-up from 1 January 2007 to 30 June 2010 at GUH.  
 
   Bio status of the pa-
tients 
Total    alive Dead 
HG 
grouped 
<=8 Count 33 76 109 
% within HG grouped 30.3% 69.7% 100.0% 
% within Bio status of 
the patients 
4.1% 38.0% 10.9% 
>8 Count 767 124 891 
% within HG grouped 86.1% 13.9% 100.0% 
% within Bio status of 
the patients 
95.9% 62.0% 89.1% 
Total Count 800 200 1000 
% within HG grouped 80.0% 20.0% 100.0% 
% within Bio status of 
the patients 
100.0% 100.0% 100.0% 
 
 
Table 4.6: Bivariate analysis of Haemoglobin count and Bio-status of the patients 
Hg = haemoglobin, grp = group 
  
B S.E. Wald df Sig. Exp(B) 
95.0% CI for EXP(B) 
  Lower Upper 
Step 1a hg_grp(1) 2.656 .230 133.574 1 .000 14.245 9.079 22.352 
Constant -1.822 .097 354.433 1 .000 .162   
a. Variable(s) entered on step 1: hg_grp.      
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Figure 4.4: Haemoglobin group distribution in the dead and alive HIV patients; GUH 
ART clinic patients chart review 
 
4.3.2.3 History of Oral Candidiasis 
 
There were a total of n=183 HIV patients (18.3%) who had a history of Oral Candidiasis. 
In a bivariate analysis there is a correlation between mortality and history of Oral Can-
didiasis, from the dead HIV patients n=112 (56%) had a history of Oral Candidiasis, 
whereas n=71 (8.9%) of the alive patients had history of Oral Candidiasis: (OR 13.068, 
95% CI 9.021 – 18.930, P < 0.0001) therefore having a history of Oral Candidiasis was 
one of the predictors of death in HIV patients who were on ART; the details are shown 
in Table 4.7, 4.8 and Figure 4.5; but with the multivariate analysis history of Oral Can-
didiasis was not a predictor of mortality (OR 1.243, 95% CI 0.612 – 2.524, P= 0.548). 
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Table 4.7: The distribution of Oral Candidiasis in the reviewed HIV patients’ charts who 
had ART follow-up at GUH from 1 January 2007 - 30 June 2010 at GUH.  
 
   Bio status of the pa-
tients 
Total    alive Dead 
history of Oral Can-
didiasis 
yes Count 71 112 183 
% within history of 
Oral Candidiasis 
38.8% 61.2% 100.0% 
% within Bio status of 
the patients 
8.9% 56.0% 18.3% 
no Count 729 88 817 
% within history of 
Oral Candidiasis 
89.2% 10.8% 100.0% 
% within Bio status of 
the patients 
91.1% 44.0% 81.7% 
Total Count 800 200 1000 
% within history of 
Oral Candidiasis 
80.0% 20.0% 100.0% 
% within Bio status of 
the patients 
100.0% 100.0% 100.0% 
 
Table 4.1: Bivariate analysis of History of Oral Candidiasis and Bio-status of the patients 
  
B S.E. Wald df Sig. Exp(B) 
95.0% CI for EXP(B) 
  Lower Upper 
Step 1a Oral C 2.570 .189 184.783 1 .000 13.068 9.021 18.930 
Constant -4.684 .272 296.729 1 .000 .009   
a. Variable(s) entered on step 1: Oral C.      
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Figure 4.5: History of Oral Candidiasis distribution in the dead and alive HIV patients; 
GUH ART clinic patients chart review 
 
4.3.2.4 History of Tuberculosis 
 
The chart review result showed that there were a total of n=215 HIV patients (21.5%) 
who had a history of TB. In a bivariate analysis there was a correlation between mortal-
ity and history of TB, from the dead HIV patient charts n=55 (27.5%) had a history TB 
whereas n=160 (20%) of the alive patients had similar history, (OR 1.517, 95% CI 1.063 
– 2.165, P = 0.022) therefore having a history of TB predicts death; the details are 
shown in Table 4.9, 4.10 and Figure 4.6, but in a multivariate analysis history of TB was 
not a significant predictor of mortality (OR 1.303, 95% CI 0.802 – 2.118, P=0.286).  
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Table 4.9: The distribution of Tuberculosis in the reviewed HIV patients’ charts who had 
ART follow-up at GUH from 1 January 2007 - 30 June 2010 at GUH. 
   Bio status of the pa-
tients 
Total    alive Dead 
history of 
TB 
yes Count 160 55 215 
% within history of TB 74.4% 25.6% 100.0% 
% within Bio status of 
the patients 
20.0% 27.5% 21.5% 
no Count 640 145 785 
% within history of TB 81.5% 18.5% 100.0% 
% within Bio status of 
the patients 
80.0% 72.5% 78.5% 
Total Count 800 200 1000 
% within history of TB 80.0% 20.0% 100.0% 
% within Bio status of 
the patients 
100.0% 100.0% 100.0% 
 
 
Table 4.10: Bivariate analysis of History of TB and Bio-status of the patients 
 
  
B S.E. Wald df Sig. Exp(B) 
95.0% CI for EXP(B) 
  Lower Upper 
Step 1a TB .417 .181 5.284 1 .022 1.517 1.063 2.165 
Constant -1.902 .241 62.061 1 .000 .149   
a. Variable(s) entered on step  1:TB      
 
 
51 
 
 
Figure 4.6: History of Tuberculosis distribution in the dead and alive HIV patients; GUH 
ART clinic patients chart review 
 
4.3.2.5 History of Cryptococcus Meningitis 
 
There was a total of n=36 HIV patients (3.6%) who had a history of Cryptococcus Men-
ingitis. In a bivariate analysis there was a correlation between mortality and history of 
Cryptococcus Meningitis, from the dead HIV patients’ n=32 (16%) had a history of 
Cryptococcus Meningitis, whereas only n=4 (0.5%) of the alive patients had similar his-
tory (OR 37.905, 95% CI 13.229 – 108.608, P < 0.0001). Therefore having a history of 
Cryptococcus Meningitis was one of the significant predictors of death in HIV patients 
who were on ART, the details are shown in Table 4.11, 4.12 and Figure 4.7. There were 
only 36 cases of Cryptococcus Meningitis in the total reviewed HIV patients’ charts, 
therefore history of Cryptococcus Meningitis was not included in the multivariate analy-
sis. 
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Table 4.11: The distribution of Cryptococcus Meningitis in the reviewed HIV patients’ 
charts who had ART follow-up at GUH from 1 January 2007 - 30 June 2010 at 
GUH. 
 
   Bio status of the pa-
tients 
Total    alive Dead 
history of crypt. men-
ingitis 
yes Count 4 32 36 
% within history of 
crypt. meningitis 
11.1% 88.9% 100.0% 
% within Bio status of 
the patients 
.5% 16.0% 3.6% 
no Count 796 168 964 
% within history of 
crypt. meningitis 
82.6% 17.4% 100.0% 
% within Bio status of 
the patients 
99.5% 84.0% 96.4% 
Total Count 800 200 1000 
% within history of 
crypt. meningitis 
80.0% 20.0% 100.0% 
% within Bio status of 
the patients 
100.0% 100.0% 100.0% 
 
Table 4.2: Bivariate analysis of History of Cryptococcus Meningitis and Bio-status of the pa-
tients 
  
B S.E. Wald df Sig. Exp(B) 
95.0% CI for EXP(B) 
  Lower Upper 
Step 1a Crypto M 3.635 .537 45.808 1 .000 37.905 13.229 108.608 
Constant -5.191 .557 86.891 1 .000 .006   
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Figure 4.7: History of Cryptococcus Meningitis distribution in the dead and alive HIV pa-
tients; GUH ART clinic patients chart review 
 
4.4 OVERVIEW OF THE RESEARCH FINDING 
 
A total of 1000 patients’ charts over the age of 18 years who started ART and had con-
tinued their follow-up at Gondar University Hospital during the study period were re-
viewed; 80% of them were alive and 20% of them were dead at the end June 2010. 
 
Mean age at the last visit was 33.5 years (range 19 – 78 years). 53.6% were female and 
46.4% were male. The median CD4 cell count was 172/µl (25th – 75th quartile = 91 – 
209/µl) and the mean CD4 cell count was 152.65 (153/µl) (Standard deviation (SD) 
78.9). 
 
Bivariate analysis revealed that a last CD4 cell count ≤ 50/µl was a significant predictor 
of mortality (OR 170.85, 95% CI 70.74 – 412.63, P < 0.0001) followed by another CD4 
cell count range of 51 – 199/µl (OR 6.74, 95% CI 2.876 – 15.795, P < 0.0001). Patients 
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who died had a mean last CD4 cell count of 57/µl compared with 176/µl for those who 
were alive at the end of the study. Similarly haemoglobin concentration ≤ 8 g/dl was 
also one of the significant predictors of mortality (OR 14.245, 95% CI 9.079 – 22.352, P 
< 0.0001). A history of TB, Oral Candidiasis and Cryptococcus Meningitis were also 
found to be correlated with an increased mortality risk of HIV patients who were on 
ART, similarly in bivariate analysis having a history of these opportunistic infections in-
cline to predict death, (OR 1.517, 95% CI 1.063 – 2.165, P = 0.022; OR 13.068, 95% CI 
9.021 – 18.93, P < 0.0001 and OR 37.905, 95% CI 13.229 – 108.608, P < 0.0001). 
 
In multivariate analysis, HIV patients with a latest CD4 cell count ≤ 50/µl had the highest 
risk of mortality (OR 155.8, 95% CI 53.57 – 453.16, P < 0.0001) followed by last CD4 
cell count of 51 – 199/µl (OR 7.070, 95% CI 2.975 – 16.8, P < 0.0001) and Female sex 
(OR 1.748, 95% CI 1.127 – 2.710, P = 0.013). Age, History of TB and History of Oral 
Candidiasis were not predictors of mortality. Because there were only 36 cases of 
Cryptococcus Meningitis, the multivariate analysis didn’t incorporate the history of 
Cryptococcus Meningitis as a predictor of mortality.        
 
4.5 CONCLUSION 
 
This chapter has addressed how the data was analysed during the study. The research 
findings are also presented in detail. The findings described in this study have also been 
in harmony with the other similar studies that were referred in the literature review part. 
 
 
 
 
 
55 
 
 
CHAPTER 5 
CONCLUSIONS AND RECOMMENDATIONS 
 
5.1 INTRODUCTION 
 
Chapter 4 described the research data analysis, presentation and description of the re-
search findings. This chapter summarises the study, provides the research overview, 
conclusions, and limitations. The chapter also provides a care plan as a contribution of 
the study and recommendations on the research findings. 
 
5.2 RESEARCH DESIGN AND METHOD 
 
The researcher conducted a retrospective cohort study using a medical chart review for 
all HIV patients who were on ART at Gondar University Hospital (GUH) ART clinic from 
01 January 2007 to 30 June 2010. Exclusion criteria were: (i) Age of < 18 years old, (ii) 
ART patients’ records who had no documented cause of death and (iii) women patients’ 
records who died while on short course ART for the purpose of prevention of mother-to-
child-transmission of HIV. 
 
A total of 1000 charts were studied which included 200 charts of dead patients and 800 
charts of alive people living with HIV (PLWHIV) who were on ART. With the aim to de-
fine predictors of mortality among PLWHIV at GUH ART clinic, data from the patients’ 
medical records were collected using a data collection instrument. The data collection 
instrument was modified from the Federal Ministry of Health (FMOH)/ HIV AIDS Preven-
tion and Control Office ART patient intake and follow-up chart which facilitated a trans-
fer of identical information from the patients’ medical documents into the data collection 
instrument. All chart reviews were conducted by the researcher. A random sample of 
100 charts were re-reviewed by a physician working at GUH ART clinic to confirm inter-
rater reliability. Inter-rater reliability was 1.00. Data was then summarized on a master 
sheet and double-entered to an electronic system which helped to correct any errors. A 
biostatistician helped the researcher to analyze and interpret the data. 
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5.3 SUMMARY AND INTERPRETATION OF THE RESEARCH FINDINGS 
 
There were several research findings which go in line with the objectives of the study. 
More or less all the findings were similar to earlier studies as evidenced by literatures 
that related to the study and mentioned in the review part. The findings and interpreta-
tions are summarized in the further discussion. 
 
5.3.1 Demographic information 
 
Sex was very important in predicting mortality. From the reviewed charts 53.6% were 
females. From the dead patients’ charts N=122 (61%) were also females. In another 
approach, out of all reviewed female patients’ charts 22.8% were dead whereas only 
16.8% of all reviewed male patients were dead at the completion of the study. When 
taking this descriptive result into a bivariate analysis, it was found to be significant in 
predicting mortality; further analysis of the result in multivariate test similarly showed a 
significant prediction potential while controlling all cofounder factors. 
 
Age was not found to be a good predictor of mortality for patients who were on ART. 
The mode for the age falls in a range 26 – 49 years old, but 23 years was the mode age 
for the individuals when one disaggregating the cluster. The mean age was 33.5 years 
and the median was 32 years. The age range for the reviewed patients’ medical record 
extends from 19 – 78 years. 
 
5.3.2 Follow-up history 
 
Two factors were found to be the strongest predictors of mortality in patients who were 
under the study from their medical records: last CD4 cell count ≤ 50/µl and last CD4 cell 
count of 51 – 199/µl. Though both predictors came from the patients CD4 cell count, the 
former one was incriminated as the most significant predictor with a very high odds ratio 
and confidence interval value. The median CD4 cell count was 172/µl (25th – 75th quar-
tile= 91 – 209/µl) and the mean was 152.65 (153/µl). The most recent CD4 cell determi-
nation of ≤ 50/µl contributed 77% of those dead patients at the completion of the study. 
 
Both haemoglobin concentration ≤ 8 g/dl and the history of opportunistic infections (OIs) 
were also correlated with mortality in the bivariate analysis, but neither haemoglobin 
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concentration nor any of the OIs history was a significant predictor when computed in a 
multivariate analysis. 
 
From all the reviewed HIV patients’ medical records, haemoglobin concentration ranged 
from 4.6 g/dl to 14 g/dl with only 10.9% of the patients had a haemoglobin concentration 
≤ 8 g/dl. The median haemoglobin concentration was 11.9 g/dl (25th – 75th quartile= 
10.1 – 12.3). 
 
In a bivariate analysis, a history of TB, Oral Candidiasis and Cryptococcus Meningitis 
conferred an increased mortality risk. When one brought these findings in to multivariate 
analysis none was able to predict mortality. Cryptococcus Meningitis was not included in 
the multivariate analysis because there were only 36 cases found from the reviewed 
documents.   
 
There were multiple presumptive OI diagnosis’s documented in patients’ medical re-
cords such as Pneumocystis Jirovecii Pneumonia (PCP), Toxoplasmosis, Herpes Zos-
ter, Kaposi’s sarcoma, Non-Hodgkin’s lymphoma and Primary Central Nervous System 
(CNS) lymphoma. However, none of the diagnoses were based on evidences for con-
firmation. Therefore, even though there were multiple OIs documented in the charts, 
only the confirmed were taken for the interest of this study. 
 
5.4 CONCLUSIONS OF THE STUDY 
 
Simple clinical and laboratory data had a huge potential to independently predict mortal-
ity in HIV patients who were on ART in Gondar, Ethiopia. These same data further 
helped to stratify risks. According to this study a female sex, CD4 cell count ≤ 50/µl and 
CD4 cell count 51 – 199/µl were found to be significant predictors of mortality. Likewise 
a history of Cryptococcus Meningitis was also a strong predictor of mortality in bivariate 
analysis even if it was not computed in multivariate analysis. Using these mortality pre-
dictors a care plan was drawn which assist adherence case managers to systematically 
reduce the prevailing death risk of PLWHIV who are on ART.  
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A medical care plan: 
 
Simple mortality predictors check boxes that will attach to medical follow-up charts of 
PLWHIV who are on ART can help to intensify medical care provision. From the check 
boxes either of female sex, CD4 cell count ≤ 50/µl, CD4 cell count 51 – 199/µl or a his-
tory of Cryptococcus meningitis is ticked, then the patient will be said to be under mor-
tality risk. Therefore these patients are expected to get a special attention with full 
package clinical and non clinical palliative care services by adherence case managers 
(Table 5.1). 
 
Table 5.1: Care plan for PLWHIV who are on ART and has mortality predictor indi-
cators 
 
 
Mortality predictors check box 
SEX                                    □Male            □Female 
CD4 cell count                     □0 – 50/µl      □ 51 – 199/µl         □≥ 200/µl 
History of Cryptococcus meningitis        □Yes               □No   
Palliative care services 
                          Clinical                                                       Non-Clinical 
 
 
 
 
 
 
 
 
 
 
 Pain management 
 Nursing care for bed ridden 
 Safe water, hygiene and 
sanitation counselling 
 Nutritional counselling  
 OIs screening 
 ART and Cotrimoxazole ad-
herence counselling  
 Psychological counselling 
and support 
 Spiritual counselling and 
support 
 Social support 
 End of life care 
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 5.5 RECOMMENDATIONS 
 
The following recommendations are helpful to improve the quality of HIV care and 
treatment service provision to GUH ART clinic in specific and to Ethiopia ART centres at 
large. The recommendations also provide an insight to FMOH, HAPCO, National and 
International Non Governmental Organizations (NGOs) working in the areas of HIV care 
and support to design an evidence based and targeted planning for HIV treatment, care 
and support policy formulation. The recommendations will also serve as bases for fur-
ther studies.  
 
Recommendations to clinicians and adherence case managers 
 
It is recommended that: 
 
 Clinicians to be more vigilant for HIV patients who are on ART with the mortality 
predictor clinical and laboratory biomarkers. The treatment should be aggres-
sive and the clinicians should preferably make their follow-up more frequent. 
 Adherence case managers give priority to support the HIV patients who are on 
ART with mortality predictors. Their adherence counselling session should be 
longer and more frequent. They also need to develop a special problem specific 
targeted care plan. 
 Adherence case managers give priority to HIV patients who are on ART with 
mortality predictor biomarkers by linking those to local NGOs who provide HIV 
patients with care and support service based on their need assessment. 
 
Recommendations to service providers and stakeholders 
 
It is recommended that: 
 
 Efforts need to be made by the ART clinics to link PLWHIV with mortality predic-
tors to Regional Civil Society Organizations which provide home based pallia-
tive care and economic strengthening supports. 
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 FMOH, HAPCO and the hospital management need to focus in ensuring that free 
OI drugs are available and further facilitation for priority in getting hospital ad-
mission beds for HIV patients who are on ART with the mortality predictors.  
5.6 CONTRIBUTIONS OF THE STUDY 
 
Following the result of this study, GUH Adherence Case Managers were assisted to re-
vise their care plan, to give more emphasis for HIV patients who are on ART with mor-
tality predictors. According to the developed medical care plan (table 5.1), the hospital’s 
adherence case managers are expected to provide a holistic palliative care service pro-
vision to their patients. The above medical care plan can also be implemented at the 
patients’ home using the town health extension workers and voluntary providers from 
the civil society organizations. 
 
5.7 LIMITATIONS OF THE STUDY 
 
The study was successfully conducted and concluded, nevertheless there were many 
limitations which hamper to generalize the findings in all geographic areas and clinical 
setups. They include the following:    
 
 There were many opportunistic infections documented in the patients’ medical 
charts, but many of them were presumptive diagnoses. For the purpose of this 
study, only definitive evidence based diagnoses were taken. Therefore, lack of 
definitive investigation modalities for many OIs affected the clinical history for OIs 
in considering them as mortality predictors. 
 All the reviewed charts were paper based medical documents, therefore poor 
documentations and illegible handwritings limit the number of variables for analy-
sis. For example, poor documentation of sequential date for patients on ART and 
patients residential location affected the scope of the analysis. 
 The retrospective study design has limited ability to collect some core factors that 
contributed to mortality of HIV patients who were on ART such as poor adher-
ence and lack of social support and real time quality of clinical service provided. 
These factors might have a significant implication in predicting mortality for HIV 
patients who are on ART. 
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 HIV RNA viral load was not available for all the patients; this value would have 
given a deep insight in predicting mortality together with CD4 cell count.   
 
5.8 CONCLUDING REMARKS 
 
Regardless of all cited limitations, the result contributed to generate information and 
knowledge for the decision support system to HIV health care providers in ensuring the 
quality of service. This study indicates that a simple clinical and laboratory data during 
the course of ART treatment can predict patients with an increased risk of death. Ag-
gressive interventions to curb these clinical and laboratory biomarkers will help ensure 
to decrease unprecedented death and maximize survival to fulfil the goal of ART. Com-
parison of the research outcomes with the situations in other ART sites in Ethiopia or 
elsewhere will enhance understanding of predictors of HIV associated mortalities in 
PLWHIV who are on ART.               
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ANNEXURES 
Annexure A: Time frame 
Activities 
M1 
(Jun) 
M2 
(July) 
M3 
(Aug) 
 
M4 
(Sept) 
 
M5 
(Oct) 
M6 
(Nov) 
 
M7 
(Dec) 
 
M8 
(Jan) 
M9 
(Feb) 
M10 
(Mar) 
M11 
(Apr) 
M12 
(May) 
M13 
(Jun) 
Prepare research 
proposal, conduct 
literature review, 
gather back-
ground data from 
GUH ART clinic 
Pre-test and vali-
dation of data 
collection instru-
ment 
x x x           
Submit proposal 
for ethical ap-
proval to UNISA 
IRB 
(assuming it 
does not take 
more than 2 
months to re-
ceive approval) 
   X          
Continue to work 
on background / 
literature review, 
while waiting for 
IRB approval 
    x x        
Submit proposal 
for ethical ap-
proval to GUH 
board. 
(assuming it 
takes 02-03 
months for ap-
proval) 
      X*       
Week #1&2: Con-
duct chart review, 
gather data 
        x     
Week #3&4: Con-
duct chart review, 
and finalizing data 
collection 
        x     
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Code data by 
hand 
Conduct data 
analysis 
         x    
Prepare manu-
script 
(Preparing of my 
dissertation) 
         x x x x 
Submit and de-
fend thesis 
          x  X** 
 
* After ethical clearance is assured form UNISA 
** Will plan to submit and defend thesis no later than November, 2011: (This time line 
may have to be changed depending up on the time it takes to receive ethical review ap-
proval both from UNISA and GUH board). 
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Annexure B: Budget 
In order to complete this study, costs for consumable materials, per diem, transportation 
to Gondar, lodging, food and supplies, UNISA annual registration fees, as well as costs 
of all professional technical supports were all covered by the researcher. The budget 
break down is presented below.  
 
Expense Source* 
Total (Calculated at an ex-
change rate of ≈ 17 Birr / 1USD 
and ≈ 2.5 Birr / 1 Rand) 
The annual UNISA registra-
tion fees for dissertation 
Self-funded  
5000 rand / 12500 birr / 
$735 USD 
Typing and printing of dis-
sertation 
Self-funded 
300 rand / 750 birr /         
$44 USD 
Preparation and photocopy-
ing of the research data col-
lection tool 
Self-funded 
800 rand / 2000 birr /         
$118 USD  
Expenses while staying in 
Gondar 
Self-funded 
500 rand / 1250 birr/       
$74 USD 
Postage, telephone calls, 
Internet time 
Self-funded 
250 rand / 625 birr /          
$37 USD 
In country travel expenses 
for PI to / from Gondar and 
Addis Ababa 
Self-funded 
1500 rand / 3750 birr /    
$221 USD 
Editing of the dissertation 
by a professional editor 
Self-funded 
1000 rand / 2500 birr /   
$147 USD 
Statistician Service Self-funded 
3000 rand / 7500 birr /   
$441 USD 
Photocopying and binding 
of 4 examination copies 
Self-funded 
100 rand / 250 birr /         
$15 USD 
The service of a profes-
sional typist to finalize the 
examination copies 
Self-funded 
3500 rand / 8750 birr /  
$515 USD 
Photocopies of final copies 
after the examiners’ com-
ments have been imple-
Self-funded 
75 rand / 187 birr / $11 
USD 
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mented 
Binding of two final copies, 
plus one unbound copy and 
one CD-Rom copy 
Self-funded 
250 rand / 625 birr /         
$37 USD 
Lodging while in Gondar for 
PI  
Self-funded 
3750 rand / 9375 birr /    
$551 USD                             
(assuming PI spend one 
month in Gondar)                  
Other expenses while stay-
ing in Gondar 
Self-funded 
1500 rand / 3750 birr /   
$221 USD 
Grand total  
21525 rand / 53812 birr / 
$3165 USD  
 
* All expenses are covered from the PI own pocket. 
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Annexure C: Data collection instrument *** 
*** Adopted from Ethiopian national HIV CARE / ART FOLLOW-UP FORM 
 
Facility name:_________________________                             Number: ________ 
Patient residences:  □Gondar town   □Outside of Gondar 
       Age: _______ years    Sex: □M □F 
Date confirmed HIV +:____ / ____ / ____ (dd/mm/yy) 
Eligible (date): __ / __ / __ (dd/mm/yy)    Elg. & Ready (date): __ / __ / __ (dd/mm/yy) 
Current status of patient  □alive  □dead  
if dead Cause of death____________________________________________________ 
 
 
Follow-up 
date 
(dd/mm/yy) 
O
I 
(O
pp
or
tu
ni
st
ic
 
in
fe
ct
io
n)
 
 W
ei
gh
t i
n 
Kg
 Functional 
Status 
(W,A,B) 
W
H
O
 s
ta
ge
 1
 - 
4 
ARV drugs 
C
D
4 
/µ
l 
H
gb
 
 AR
V 
dr
ug
s 
Adh 
(G,F,P) 
Side 
effect 
Reason 
for 
change 
           
           
           
           
           
           
 
 
Key:     W = Working      A = Ambulatory      B = Bed ridden    
             G = Good           F = Fair                  P = Poor    
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Annexure D: Federal Ministry of Health, Ethiopia HIV care/ART follow-up form 
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Annexure E: Letter asking for permission to conduct the research at Gondar Uni-
versity hospital 
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Annexure F: Approval from Gondar University Hospital 
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Annexure G: Ethical clearance from UNISA 
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Annexure H: Ethical clearance from Gondar University 
 
 
 
